<SEC-DOCUMENT>0001193125-16-766247.txt : 20161114
<SEC-HEADER>0001193125-16-766247.hdr.sgml : 20161111
<ACCEPTANCE-DATETIME>20161110212902
ACCESSION NUMBER:		0001193125-16-766247
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20161110
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20161114
DATE AS OF CHANGE:		20161110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BOVIE MEDICAL Corp
		CENTRAL INDEX KEY:			0000719135
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				112644611
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31885
		FILM NUMBER:		161989851

	BUSINESS ADDRESS:	
		STREET 1:		4 MANHATTANVILLE ROAD, SUITE 106
		CITY:			PURCHASE
		STATE:			NY
		ZIP:			10577
		BUSINESS PHONE:		800-537-2790

	MAIL ADDRESS:	
		STREET 1:		4 MANHATTANVILLE ROAD, SUITE 106
		CITY:			PURCHASE
		STATE:			NY
		ZIP:			10577

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL CORP
		DATE OF NAME CHANGE:	19990216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AN CON GENETICS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d287359d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION&nbsp;13 OR 15(D) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>November&nbsp;10, 2016 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>BOVIE MEDICAL
CORPORATION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>012183</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>11-2644611</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4 Manhattanville Road, Suite 106 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Purchase, New York 10577 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(914) 468-4009 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P></TD></TR>
</TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Entry Into a Material Definitive Agreement </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2016, Bovie Medical Corporation (the
&#147;Company&#148;) entered into an underwriting agreement (the &#147;Underwriting Agreement&#148;) with certain selling stockholders of the Company (the &#147;Selling Stockholders&#148;) and Piper Jaffray&nbsp;&amp; Co. (the
&#147;Underwriter&#148;) relating to public offerings of the Company&#146;s common stock, par value $0.001 per share (the &#147;Shares&#148;) at a public offering price of $4.00 per share. A primary offering of 1,500,000 Shares will be made by the
Company and a secondary offering of 1,500,000 Shares will be made by the Selling Stockholders. The Company and the Selling Stockholders also granted the Underwriter a 30-day option to purchase up to an additional 450,000 Shares to cover
over-allotments, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net proceeds to the Company from the sale of the Shares, after deducting the Underwriter&#146;s discounts and commissions
and estimated offering expenses payable by the Company, are expected to be approximately $5,473,000, or approximately $6,319,000 if the underwriters exercise their overallotment option in full. The offerings are expected to close on
November&nbsp;16, 2016, subject to the satisfaction of customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Underwriting Agreement is qualified
in its entirety by reference to such Underwriting Agreement, which is filed as Exhibit 1.1 hereto and is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shares are
being offered and sold by the Company pursuant to a prospectus dated December&nbsp;16, 2014 and a prospectus supplement filed with the Securities and Exchange Commission (the &#147;SEC&#148;) on November&nbsp;10, 2016, which are part of the
Company&#146;s effective shelf registration statement on Form S-3 (File No.&nbsp;333-200986) filed with the SEC on December&nbsp;15, 2014. The Shares are being offered and sold by the Selling Stockholders pursuant to a prospectus dated
April&nbsp;24, 2015 and a prospectus supplement filed with the SEC on November&nbsp;10, 2016, which are part of the Company&#146;s effective registration statement on Form S-3 (File No.&nbsp;333-203422) filed with the SEC on April&nbsp;15, 2015.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Regulation FD Disclosure </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;10, 2016, the Company issued a press release announcing the
pricing of the offerings. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is furnishing the information in this Item&nbsp;7.01 and in Exhibit 99.1 to comply with Regulation FD. Such information, including Exhibit 99.1,
shall not be deemed &#147;filed&#148; for any purpose, including for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that Section. The
information in this Item&nbsp;7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Securities Act of 1933 as amended, or the Exchange Act, regardless of any general incorporation language in such
filings. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit&nbsp;No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement, dated November 10, 2016, by and among Bovie Medical Corporation, the Selling Stockholders named therein, and Piper Jaffray &amp; Co.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release dated November 10, 2016</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;10, 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">BOVIE MEDICAL CORPORATION</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By: <U>/s/ Robert L.
Gershon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Robert L. Gershon</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d287359dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3,000,000 Shares </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BOVIE
MEDICAL CORPORATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNDERWRITING AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">November 10, 2016 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PIPER JAFFRAY &amp; CO. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Bancorp Center </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">800 Nicollet Mall </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Minneapolis, Minnesota&nbsp;55402 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bovie Medical Corporation, a Delaware corporation (the <B><I>&#147;Company&#148;</I></B>), and the stockholders of the Company listed in
Schedule I hereto (the <B><I>&#147;Selling Stockholders&#148;</I></B>) severally propose to sell to the several Underwriters named in Schedule II hereto (the <B><I>&#147;Underwriters&#148;</I></B>) an aggregate of 3,000,000 shares (the
<B><I>&#147;Firm Shares&#148;</I></B>) of Common Stock, $0.001 par value per share (the <B><I>&#147;Common Stock&#148;</I></B>), of the Company.&nbsp;The Firm Shares consist of 1,500,000 authorized but unissued shares of Common Stock to be issued
and sold by the Company and&nbsp;1,500,000 shares of Common Stock to be sold by the Selling Stockholders.&nbsp;The Company and the Selling Stockholders have also granted to the several Underwriter an option to purchase up to 225,000 and 225,000
additional shares of Common Stock, respectively, on the terms and for the purposes set forth in Section 3 hereof (the <B><I>&#147;Option Shares&#148;</I></B>).&nbsp;The Firm Shares and any Option Shares purchased pursuant to this Purchase Agreement
are herein collectively called the <B><I>&#147;Securities.&#148; </I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Selling Stockholders hereby confirm their
agreement with respect to the sale of the Securities to the several Underwriters, for whom Piper Jaffray &amp; Co. in acting as representative (the <B><I>&#147;Representative&#148;</I></B>). To the extent there are no additional Underwriters listed
on <U>Schedule II</U> other than you, the term Representative as used in this Underwriting Agreement shall mean you, as Underwriter, and the terms&nbsp;Representative and Underwriters shall mean either the singular or plural as the context
requires.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <B><I>Registration Statements and Prospectuses</I></B>.&nbsp;The Company has prepared and filed with the Securities and
Exchange Commission (the <B><I>&#147;Commission&#148;</I></B>) registration statements on Form S-3 (File Nos. 333-2009886 and 333-203422) under the Securities Act of 1933, as amended (the <B><I>&#147;Securities Act&#148;
</I></B>or&nbsp;<B><I>&#147;Act&#148;</I></B>) and the rules and regulations (the <B><I>&#147;Rules and Regulations&#148;</I></B>) of the Commission thereunder, and such amendments to such registration statements as may have been required to the
date of this Agreement.&nbsp;Such registration statements have been declared effective by the Commission.&nbsp;Each part of such registration statements, including the amendments, exhibits and any schedules thereto, the documents incorporated by
reference therein pursuant to Item 12 of Form S-3 under the Securities Act and the documents and information otherwise deemed to be a part </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
thereof or included therein by Rule 430B under the Securities Act (the <B><I>&#147;Rule 430B Information&#148;</I></B>) or otherwise pursuant to the Rules and Regulations, as of the time each
Registration Statement became effective, is herein called the <B><I>&#147;Registration Statement,&#148;</I></B> and collectively, the <I></I><B>&#147;</B><I></I><B><I>Registration Statements&#148;</I></B>. Any registration statement filed by the
Company pursuant to Rule 462(b) under the Securities Act is called the &#147;Rule 462(b) Registration Statement&#148; and, from and after the date and time of filing of the Rule 462(b) Registration Statement, the term &#147;Registration
Statement&#148; shall include the Rule 462(b) Registration Statement.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each prospectus in the form in which it has most recently been filed
with the Commission on or prior to the date of this Agreement with respect to either Registration Statement is herein called a <B><I>&#147;Base Prospectus,&#148; </I></B>and collectively, the <B><I>&#147;Base Prospectuses.&#148;</I></B>&nbsp;Each
preliminary prospectus supplement to the Base Prospectuses (including the Base Prospectuses as so supplemented), that describes the Securities and the offering thereof, that omitted the Rule 430B Information and that was used prior to the filing of
the final prospectus supplements referred to in the following sentence is herein called a <B><I>&#147;Preliminary Prospectus&#148; </I></B>and collectively, the <B><I>&#147;Preliminary Prospectuses.&#148; </I></B>Promptly after execution and
delivery of this Agreement, the Company will prepare and file with the Commission final prospectus supplements to the Base Prospectuses relating to the Securities and the offering thereof in accordance with the provisions Rule 430B and Rule 424(b)
of the Rules and Regulations.&nbsp;Such final supplemental form of prospectuses (including the Base Prospectuses as so supplemented), in the forms filed with the Commission pursuant to Rule 424(b) is herein called the <B><I>&#147;Prospectuses,&#148;
</I></B>and each a <B><I>&#147;Prospectus.&#148; </I></B>Any reference herein to a Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to include the documents incorporated by reference therein pursuant to Item 12
of Form S-3 under the Securities Act as of the date of such prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Agreement, all references to the
Registration Statements, the Rule 462(b) Registration Statements, the Base Prospectuses, any Preliminary Prospectus, the Prospectuses or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the
Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System or any successor system thereto (<B><I>&#147;EDGAR&#148;</I></B>).&nbsp;All references in this Agreement to financial statements and schedules and other information
which is &#147;described,&#148; &#147;contained,&#148; &#147;included&#148; or &#147;stated&#148; in the Registration Statements, the Base Prospectuses, any Preliminary Prospectus or the Prospectuses (or other references of like import) shall be
deemed to mean and include all such financial statements and schedules and other information which is incorporated by reference in or otherwise deemed by the Rules and Regulations to be a part of or included in the Registration Statements, the Base
Prospectuses, any Preliminary Prospectus or the Prospectuses, as the case may be; and all references in this Agreement to amendments or supplements to the Registration Statements, the Base Prospectuses, any Preliminary Prospectus or the Prospectuses
shall be deemed to mean and include the subsequent filing of any document under the Securities Exchange Act of 1934, as amended (the <B><I>&#147;Exchange Act&#148;</I></B>), and which is deemed to be incorporated therein by reference therein or
otherwise deemed by the Rules and Regulations to be a part thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B><I>Representations and Warranties of the Company and the Selling Stockholders</I></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <I><U>Representations and Warranties of the Company</U></I>. The Company represents and warrants to, and agrees with, the several
Underwriters as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <I><U>Registration Statement and Prospectuses</U></I>.&nbsp;No order preventing or suspending
the use of any Preliminary Prospectus or any Prospectus (or any supplement thereto) has been issued by the Commission and no proceeding for that purpose has been initiated or is pending or, to the knowledge of the Company, threatened by the
Commission. As of the time each part of each Registration Statement (or any post-effective amendment thereto) became or becomes effective (including each deemed effective date with respect to the Underwriters pursuant to Rule 430B or otherwise under
the Securities Act), such part conformed or will conform in all material respects to the requirements of the Act and the Rules and Regulations.&nbsp;Upon the filing or first use within the meaning of the Rules and Regulations, each Preliminary
Prospectus and each Prospectus (or any supplement to either) conformed or will conform in all material respects to the requirements of the Act and the Rules and Regulations.&nbsp;Each Registration Statement and any post-effective amendment thereto
has become effective under the Securities Act.&nbsp;The Company has complied to the Commission&#146;s satisfaction with all requests of the Commission for additional or supplemental information.&nbsp;No stop order suspending the effectiveness of the
Registration Statements, any post-effective amendment or any part thereof is in effect and no proceedings for such purpose have been instituted or are pending or, to the knowledge of the Company, are threatened by the Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) <I><U>Accurate Disclosure</U></I>.&nbsp;Each Preliminary Prospectus, at the time of filing thereof or the time of first
use within the meaning of the Rules and Regulations, did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading.&nbsp;Neither the Registration Statements nor any amendment thereto, at the effective time of each part thereof, at the First Closing Date (as defined below) or at the Second Closing Date (as defined
below), contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the Time of
Sale (as defined below), neither (A) the Time of Sale Disclosure Package (as defined below) nor (B) any issuer free writing prospectus (as defined below), when considered together with the Time of Sale Disclosure Package, included an untrue
statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. Neither the Prospectuses nor any supplement thereto, as of
their issue date, at the time of any filing with the Commission pursuant to Rule 424(b) of the Rules and Regulations, at the First Closing Date or at the Second Closing, included, includes or will include an untrue statement of a material fact or
omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.&nbsp;The representations and warranties in this Section 2(a)(ii) shall
not apply to statements in or omissions from any Preliminary Prospectus, the Registration Statements (or any amendment thereto), the Time of Sale </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Disclosure Package or the Prospectuses (or any supplement thereto) made in reliance upon, and in conformity with, written information furnished to the Company by you, or by any Underwriter
through you, specifically for use in the preparation of such document, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 6(f).</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each reference to an <B><I>&#147;issuer free writing prospectus&#148;</I></B> herein means an issuer free writing prospectus as defined in Rule
433 of the Rules and Regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Time of Sale Disclosure Package&#148;</I></B> means the Preliminary Prospectuses dated
November 10, 2016, any free writing prospectus set forth on Schedule III and the information on Schedule V, all considered together. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each
reference to a <B><I>&#147;free writing prospectus&#148;</I></B> herein means a free writing prospectus as defined in Rule 405 of the Rules and Regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>&#147;Time of Sale&#148;</I></B> means 8:30 a.m. (Eastern time) on the date of this Agreement.</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) <I><U>Issuer Free Writing Prospectuses</U></I>. (A) Each Issuer Free Writing Prospectus does not include any information
that conflicts with the information contained in the Registration Statements, any Preliminary Prospectus or the Prospectuses.&nbsp;The foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus based upon
and in conformity with written information furnished to the Company by you or by any Underwriter through you specifically for use therein; it being understood and agreed that the only such information furnished by any Underwriter consists of the
information described as such in Section 6(f). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(B) (1) At the earliest time after the filing of each Registration
Statement that the Company or another offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Securities and (2) at the date hereof, the Company was not and is not an &#147;ineligible
issuer,&#148; as defined in Rule 405 under the Securities Act, including the Company or any subsidiary in the preceding three years not having been convicted of a felony or misdemeanor or having been made the subject of a judicial or administrative
decree or order as described in Rule 405 of the Rules and Regulations (without taking account of any determination by the Commission pursuant to Rule 405 of the Rules and Regulations that it is not necessary that the Company be considered an
ineligible issuer), nor an &#147;excluded issuer&#148; as defined in Rule 164 under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(C) Each Issuer
Free Writing Prospectus satisfied, as of its issue date and at all subsequent times to the Time of Sale, all other conditions to use thereof as set forth in Rules 164 and 433 under the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) <I><U>No Other Offering Materials</U></I>.&nbsp;The Company has not
distributed and will not distribute any prospectus or other offering material in connection with the offering and sale of the Securities other than any Preliminary Prospectus, the Time of Sale Disclosure Package or the Prospectuses or other
materials permitted by the Act to be distributed by the Company; <I>provided, however,</I> that, except as set forth on Schedule III, the Company has not made and will not make any offer relating to the Securities that would constitute a free
writing prospectus, except in accordance with the provisions of Section 4(a)(xv) of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) <I><U>Financial
Statements</U></I>.&nbsp;The financial statements of the Company, together with the related notes, set forth or incorporated by reference in the Registration Statements, the Time of Sale Disclosure Package and the Prospectuses comply in all material
respects with the requirements of the Securities Act and the Exchange Act and fairly present in all material respects the financial condition of the Company and its consolidated subsidiaries as of the dates indicated and the results of operations
and changes in cash flows for the periods therein specified in conformity with generally accepted accounting principles in the United States consistently applied throughout the periods involved; the supporting schedules included in the Registration
Statements present fairly the information required to be stated therein; all non-GAAP financial information included in the Registration Statements, if any, the Time of Sale Disclosure Package and the Prospectuses comply with the requirements of
Regulation G and Item 10 of Regulation S-K under the Act; and, except as disclosed in the Time of Sale Disclosure Package and the Prospectuses, there are no material off-balance sheet arrangements (as defined in Regulation S-K under the Act, Item
303(a)(4)(ii)) or any other relationships with unconsolidated entities or other persons, that would reasonably be expected to have a material current or, to the Company&#146;s knowledge, material future effect on the Company&#146;s financial
condition, results of operations, liquidity, capital expenditures, capital resources or significant components of revenue or expenses.&nbsp;No other financial statements or schedules are required to be included in the Registration Statements, the
Time of Sale Disclosure Package or the Prospectuses.&nbsp;To the Company&#146;s knowledge, Frazier &amp; Deeter, LLC, which has expressed its opinion with respect to the financial statements and schedules filed as a part of each Registration
Statement and included in each Registration Statement, the Time of Sale Disclosure Package and the Prospectuses, is (x) an independent public accounting firm within the meaning of the Act and the Rules and Regulations, (y) a registered public
accounting firm (as defined in Section 2(a)(12) of the Sarbanes-Oxley Act of 2002 (the <B><I>&#147;Sarbanes-Oxley Act&#148;</I></B>)) and (z) not in violation of the auditor independence requirements of the Sarbanes-Oxley Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vi) <I><U>Organization and Good Standing</U></I>.&nbsp;Each of the Company and its subsidiaries has been duly organized and is
validly existing as a corporation in good standing under the laws of its jurisdiction of incorporation. Each of the Company and its subsidiaries has full corporate power and authority to own its properties and conduct its business as currently being
carried on and as described in the Registration Statements, the Time of Sale Disclosure Package and the Prospectuses, and is duly qualified to do business as a foreign corporation in good standing in each jurisdiction in which it owns or leases real
property or in which the conduct of its business makes such qualification necessary and in which the failure to so qualify would reasonably be expected to have a material adverse effect upon the business, prospects, management, properties,
operations, condition (financial or otherwise) or results of operations of the Company and its subsidiaries, taken as a whole (<B><I>&#147;Material Adverse Effect&#148;</I></B>). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vii) <I><U>Absence of Certain Events</U></I>.&nbsp;Except as contemplated in the
Time of Sale Disclosure Package and in each Prospectus, subsequent to the respective dates as of which information is given in the Time of Sale Disclosure Package, neither the Company nor any of its subsidiaries has incurred any material liabilities
or obligations, direct or contingent, or entered into any material transactions, or declared or paid any dividends or made any distribution of any kind with respect to its capital stock; and there has not been any change in the capital stock (other
than a change in the number of outstanding shares of Common Stock due to the issuance of shares upon the exercise of outstanding options or warrants or conversion of convertible securities), or any material change in the short-term or long-term debt
(other than as a result of the conversion of convertible securities), or any issuance of options, warrants, convertible securities or other rights to purchase the capital stock, of the Company or any of its subsidiaries, or any material adverse
change in the general affairs, condition (financial or otherwise), business, prospects, management, properties, operations or results of operations of the Company and its subsidiaries, taken as a whole (<B><I>&#147;Material Adverse
Change&#148;</I></B>) or any development which could reasonably be expected to result in any Material Adverse Change. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(viii) <I><U>Absence of Proceedings</U></I>.&nbsp;Except as set forth in the Time of Sale Disclosure Package and in each
Prospectus, there is not pending or, to the knowledge of the Company, threatened or contemplated, any action, suit or proceeding (a) to which the Company or any of its subsidiaries is a party or (b) which has as the subject thereof any officer or
director of the Company or any subsidiary, any employee benefit plan sponsored by the Company or any subsidiary or any property or assets owned or leased by the Company or any subsidiary before or by any court or Governmental Authority (as defined
below), or any arbitrator, which, individually or in the aggregate, would reasonably be expected to result in any Material Adverse Change, or would materially and adversely affect the ability of the Company to perform its obligations under this
Agreement or which are otherwise material in the context of the sale of the Securities.&nbsp;There are no current or, to the knowledge of the Company, pending, legal, governmental or regulatory actions, suits or proceedings (x) to which the Company
or any of its subsidiaries is subject or (y) which has as the subject thereof any officer or director of the Company or any subsidiary, any employee plan sponsored by the Company or any subsidiary or any property or assets owned or leased by the
Company or any subsidiary, that are required to be described in the Registration Statements, Time of Sale Disclosure Package and Prospectuses by the Act or by the Rules and Regulations and that have not been so described. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ix) <I><U>Disclosure of Legal Matters</U></I>. There are no statutes, regulations, contracts or documents that are required to
be described in the Registration Statements, in the Time of Sale Disclosure Package and in the Prospectuses or required to be filed as exhibits to the Registration Statements by the Securities Act or by the Rules and Regulations that have not been
so described or filed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(x) <I><U>Authorization; No Conflicts; Authority</U></I>.&nbsp;This Agreement has
been duly authorized, executed and delivered by the Company, and constitutes a valid, legal and binding obligation of the Company, enforceable in accordance with its terms, except as rights to indemnity hereunder may be limited by federal or state
securities laws and except as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally and subject to general principles of equity. The execution, delivery and
performance by the Company of this Agreement and the consummation of the transactions herein contemplated will not (A) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in
the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the
Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject, (B) result in any violation of the provisions
of the Company&#146;s charter or by-laws or (C) result in the violation of any law or statute or any judgment, order, rule, regulation or decree of any court or arbitrator or federal, state, local or foreign governmental agency or regulatory
authority having jurisdiction over the Company or any of its subsidiaries or any of their properties or assets (each, a <B><I>&#147;Governmental Authority&#148;</I></B>), except in the case of clause (A) as would not result in a Material Adverse
Effect.&nbsp;No consent, approval, authorization or order of, or registration or filing with any Governmental Authority is required for the execution, delivery and performance by the Company of this Agreement or for the consummation of the
transactions contemplated hereby, including the issuance or sale of the Securities by the Company, except such as may be required under the Act, the rules of the Financial Industry Regulatory Authority (<B><I>&#147;FINRA&#148;</I></B>) or state
securities or blue sky laws; and the Company has full power and authority to enter into this Agreement and to consummate the transactions contemplated hereby, including the authorization, issuance and sale of the Securities by the Company as
contemplated by this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xi) <I><U>Capitalization; the Securities; Registration Rights</U></I>.&nbsp;All of the
issued and outstanding shares of capital stock of the Company, including the outstanding shares of Common Stock, are&nbsp;duly authorized and validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state and
foreign securities laws and were not issued in violation of or subject to any preemptive rights or other rights to subscribe for or purchase securities that have not been waived in writing (a copy of which has been delivered to counsel to the
Representative); the Securities which may be sold hereunder by the Company have been duly authorized and, when issued, delivered and paid for in accordance with the terms of this Agreement, will have been validly issued and will be fully paid and
nonassessable; and the capital stock of the Company, including the Common Stock, conforms to the description thereof in the Registration Statements, in the Time of Sale Disclosure Package and in the Prospectuses.&nbsp;Except as otherwise stated in
the Registration Statements, in the Time of Sale Disclosure Package and in the Prospectuses, (A) there are no preemptive rights or other rights to subscribe for or to purchase, or any restriction upon the voting or transfer of, any shares of Common
Stock pursuant to the Company&#146;s charter, by-laws or any agreement or other instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
(B) neither the filing of the Registration Statements nor the offering or sale of the Securities as contemplated by this Agreement gives rise to any rights for or relating to the registration of
any shares of Common Stock or other securities of the Company (collectively <B><I>&#147;Registration Rights&#148;</I></B>) and (C) any person to whom the Company has granted Registration Rights has agreed not to exercise such rights until after
expiration of the Lock-Up Period (as defined below).&nbsp;All of the issued and outstanding shares of capital stock of each of the Company&#146;s subsidiaries have been duly and validly authorized and issued and are fully paid and nonassessable,
and, except as otherwise described in the Registration Statements, in the Time of Sale Disclosure Package and in the Prospectuses, the Company owns of record and beneficially, free and clear of any security interests, claims, liens, proxies,
equities or other encumbrances, all of the issued and outstanding shares of such stock.&nbsp;The Company has an authorized and outstanding capitalization as set forth in the Registration Statements, in the Time of Sale Disclosure Package and in the
Prospectuses under the caption &#147;Capitalization.&#148; The Common Stock (including the Securities) conforms in all material respects to the description thereof contained in the Time of Sale Disclosure Package and the Prospectuses.</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xii) <I><U>Stock Options</U></I>.&nbsp;Except as described in the Registration Statements, in the Time of Sale Disclosure
Package and in the Prospectuses, there are no options, warrants, agreements, contracts or other rights in existence to purchase or acquire from the Company or any subsidiary of the Company any shares of the capital stock of the Company or any
subsidiary of the Company.&nbsp;The description of the Company&#146;s stock option, stock bonus and other stock plans or arrangements (the <B><I>&#147;Company Stock Plans&#148;</I></B>), and the options (the <B><I>&#147;Options&#148;</I></B>) or
other rights granted thereunder, set forth in the Time of Sale Disclosure Package and the Prospectuses accurately and fairly presents in all material respects the information required to be shown with respect to such plans, arrangements, options and
rights.&nbsp;Each grant of an Option (A) was duly authorized no later than the date on which the grant of such Option was by its terms to be effective by all necessary corporate action, including, as applicable, approval by the board of directors of
the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by
each party thereto and (B) was made in accordance with the terms of the applicable Company Stock Plan, and all applicable laws and regulatory rules or requirements, including all applicable federal securities laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xiii) <I><U>Compliance with Laws</U></I>.&nbsp;The Company and each of its subsidiaries holds, and is operating in compliance
in all material respects with, all franchises, grants, authorizations, licenses, permits, easements, consents, certificates and orders of any Governmental Authority or self-regulatory body required for the conduct of its business and all such
franchises, grants, authorizations, licenses, permits, easements, consents, certifications and orders are valid and in full force and effect; and neither the Company nor any of its subsidiaries has received notice of any revocation or modification
of any such material franchise, grant, authorization, license, permit, easement, consent, certification or order or has reason to believe that any such franchise, grant, authorization, license, permit, easement, consent, certification or order will
not be renewed in the ordinary course; and the Company and each of its subsidiaries is in compliance in all material respects with all applicable federal, state, local and foreign laws, regulations, orders and decrees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xiv) <I><U>Ownership of Assets</U></I>.&nbsp;The Company and its subsidiaries
have good and marketable title to all property (whether real or personal) described in the Registration Statements, in the Time of Sale Disclosure Packages and in the Prospectuses as being owned by them, in each case free and clear of all liens,
claims, security interests, other encumbrances or defects except such as are described in the Registration Statements, in the Time of Sale Disclosure Package and in the Prospectuses and except for such property that is not material to the conduct of
their business.&nbsp;The property held under lease by the Company and its subsidiaries is held by them under valid, subsisting and enforceable leases with only such exceptions with respect to any particular lease as do not interfere in any material
respect with the conduct of the business of the Company or its subsidiaries.</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xv) <I><U>Intellectual
Property</U></I>.&nbsp;The Company and each of its subsidiaries owns, possesses, or can acquire on reasonable terms, all Intellectual Property necessary for the conduct of the Company&#146;s and it subsidiaries&#146; business as now conducted or as
described in the Registration Statements, the Time of Sale Disclosure Packages and the Prospectuses to be conducted, except as such failure to own, possess, or acquire such rights would not reasonably be expected to result in a Material Adverse
Effect.&nbsp;Furthermore, (A) to the knowledge of the Company, there is no infringement, misappropriation or violation by third parties of any such Intellectual Property, except as such infringement, misappropriation or violation would not
reasonably be expected to result in a Material Adverse Effect; (B) there is no pending or, to the knowledge of the Company, threatened, action, suit, proceeding or claim by others challenging the Company&#146;s or any of its subsidiaries&#146;
rights in or to any such Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (C) the Intellectual Property owned by the Company and its subsidiaries, and to the knowledge of the
Company, the Intellectual Property licensed to the Company and its subsidiaries, has not been adjudged invalid or unenforceable, in any material respect, and there is no pending or, to the knowledge of the Company, threatened action, suit,
proceeding or claim by others challenging the validity or scope of any such Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such claim; (D) there is no pending or, to the knowledge of the
Company, threatened action, suit, proceeding or claim by others that the Company or any of its subsidiaries infringes, misappropriates or otherwise violates any Intellectual Property or other proprietary rights of others, neither the Company or any
of its subsidiaries has received any written notice of such claim and the Company is unaware of any other fact which would form a reasonable basis for any such claim; and (E) to the Company&#146;s knowledge, no employee of the Company or any of its
subsidiaries is in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a
former employer where the basis of such violation relates to such employee&#146;s employment with the Company nor any of its subsidiaries or actions undertaken by the employee while employed with the Company or any of its subsidiaries, except as
such violation would not reasonably be expected to result in a Material Adverse Effect.&nbsp;<B><I>&#147;Intellectual Property&#148;</I></B> shall mean all patents, patent applications, trade and service marks, trade and service&nbsp;mark
registrations, trade names, copyrights, licenses, inventions, trade secrets, domain names, technology, know-how and other intellectual property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xvi) <I><U>No Violations or Defaults</U></I>.&nbsp;Neither the Company nor any
of its subsidiaries is in violation of its respective charter, by-laws or other organizational documents, or in breach of or otherwise in default, and no event has occurred which, with notice or lapse of time or both, would constitute such a default
in the performance of any obligation, agreement or condition contained in any bond, debenture, note, indenture, loan agreement or any other contract, lease or other instrument to which it is subject or by which any of them may be bound, or to which
any of the property or assets of the Company or any of its subsidiaries is subject where such breach or default would reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xvii) <I><U>Taxes</U></I>.&nbsp;The Company and its subsidiaries have timely filed all federal, state, local and foreign
income and franchise tax returns required to be filed and are not in default in&nbsp;the payment of any taxes which were payable pursuant to said returns or any assessments with respect thereto, other than any which the Company or any of its
subsidiaries is contesting in good faith.&nbsp;There is no pending dispute with any taxing authority relating to any of such returns, and the Company has no knowledge of any proposed liability for any tax to be imposed upon the properties or assets
of the Company for which there is not an adequate reserve reflected in the Company&#146;s financial statements included in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xviii) <I><U>Exchange Listing and Exchange Act Registration</U></I>.&nbsp;The Common Stock is registered pursuant to Section
12(b) of the Exchange Act and is included or approved for listing on the New York Stock Exchange&nbsp;and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Common Stock under the
Exchange Act or delisting the Common Stock from the New York Stock Exchange nor has the Company received any notification that the Commission or the New York Stock Exchange is contemplating terminating such registration or listing. The Company has
complied in all material respects with the applicable requirements of the New York Stock Exchange for maintenance of inclusion&nbsp;of the Common Stock thereon. The Company has filed an application to include the Securities on the New York Stock
Exchange.&nbsp;Except as previously disclosed to counsel for the Underwriters or as set forth in the Time of Sale Disclosure Package and the Prospectuses, to the knowledge of the Company, no beneficial owners of the Company&#146;s capital stock or
subordinated debt who, together with their associated persons and affiliates, hold in the aggregate 10% or more of such capital stock or subordinated debt, have any direct or indirect association or affiliate with a FINRA member. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xix) <I><U>Ownership of Other Entities</U></I>.&nbsp;Other than the subsidiaries of the Company listed on <U>Schedule IV</U>
hereto&nbsp;the Company, directly or indirectly, owns no capital stock or other equity or ownership or proprietary interest in any corporation, partnership, association, trust or other entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xx) <I><U>Internal Controls</U></I>.&nbsp;The Company and its subsidiaries
maintain a system of internal accounting controls sufficient to provide reasonable assurances that (i) transactions are executed in accordance with management&#146;s general or specific authorization; (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with generally accepted accounting principles in the United States and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management&#146;s
general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.&nbsp;Except as disclosed in the Registration
Statements, in the Time of Sale Disclosure Package and in the Prospectuses, the Company&#146;s internal control over financial reporting is effective and none of the Company, its board of directors and audit committee is aware of any
&#147;significant deficiencies&#148; or &#147;material weaknesses&#148; (each as defined by the Public Company Accounting Oversight Board) in its internal control over financial reporting, or any fraud, whether or not material, that involves
management or other employees of the Company and its subsidiaries who have a significant role in the Company&#146;s internal controls; and since the end of the latest audited fiscal year, there has been no change in the Company&#146;s internal
control over financial reporting (whether or not remediated) that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting.&nbsp;The Company&#146;s board of directors has,
subject to the exceptions, cure periods and the phase in periods specified in the applicable stock exchange rules (<B><I>&#147;Exchange Rules&#148;</I></B>), validly appointed an audit committee to oversee internal accounting controls whose
composition satisfies the applicable requirements of the Exchange Rules and the Company&#146;s board of directors and/or the audit committee has adopted a charter that satisfies the requirements of the Exchange Rules. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xxi) <I><U>No Brokers or Finders</U></I>.&nbsp;Other than as contemplated by this Agreement, the Company has not incurred any
liability for any finder&#146;s or broker&#146;s fee or agent&#146;s commission in connection with the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xxii) <I><U>Insurance</U></I>.&nbsp;The Company and each of its subsidiaries carries, or is covered by, insurance from
reputable insurers in such amounts and covering such risks as is adequate for the conduct of its business and the value of its properties and the properties of its subsidiaries and as is customary for companies engaged in similar businesses in
similar industries; all policies of insurance and any fidelity or surety bonds insuring the Company or any of its subsidiaries or its business, assets, employees, officers and directors are in full force and effect; the Company and its subsidiaries
are in compliance in all material respects with the terms of such policies and instruments; there are no claims by the Company or any of its subsidiaries under any such policy or instrument as to which any insurance company is denying liability or
defending under a reservation of rights clause; neither the Company nor any of its subsidiaries has been refused any insurance coverage sought or applied for; and neither the Company nor any of its subsidiaries has reason to believe that it will not
be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not reasonably be expected to have a Material
Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xxiii) <I><U>Investment Company Act</U></I>.&nbsp;The Company is not and, after
giving effect to the offering and sale of the Securities, will not be an &#147;investment company,&#148; as such term is defined in the Investment Company Act of 1940, as amended. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xxiv) <I><U>Eligibility to use Form S-3</U></I>.&nbsp;The conditions for use of Form S-3, set forth in the General
Instructions thereto, have been satisfied by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xxv) <I><U>Incorporated Documents</U></I>.&nbsp;The documents
incorporated by reference in the Time of Sale Disclosure Package and in the Prospectuses, when they became effective or were filed with the Commission, as the case may be, conformed in all material respects to the requirements of the Securities Act
or the Exchange Act, as applicable, and were filed on a timely basis with the Commission and none of such documents contained an untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the
light of the circumstances under which they were made, not misleading; any further documents so filed and incorporated by reference in the Time of Sale Disclosure Package or in the Prospectuses, when such documents are filed with the Commission,
will conform in all material respects to the requirements of the Exchange Act, and will not contain an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xxvi)&nbsp;<I><U>Sarbanes-Oxley Act</U></I>.&nbsp;The Company is in
compliance in all material respects with all applicable provisions of the Sarbanes-Oxley Act and the rules and regulations of the Commission thereunder applicable to the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xxvii)&nbsp;<I><U>Disclosure Controls</U></I>.&nbsp;The Company has established and maintains disclosure controls and
procedures (as defined in Rules 13a-14 and 15d-14 under the Exchange Act) and such controls and procedures are effective in ensuring that material information relating to the Company, including its subsidiaries, is made known to the principal
executive officer and the principal financial officer.&nbsp;The Company has utilized such controls and procedures in preparing and evaluating the disclosures in the Registration Statements, in the Time of Sale Disclosure Package and in the
Prospectuses.</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xxviii)&nbsp;<I><U>Anti-Bribery and Anti-Money Laundering Laws</U></I>.&nbsp;Neither the Company nor its
subsidiaries,&nbsp;nor, to the knowledge of the Company, any their respective affiliates, officers, directors, managers, agents or employees, has violated and its participation in the offering will not violate, and the Company and each of its
subsidiaries has instituted and maintains policies and procedures designed to ensure continued compliance by the Company, its subsidiaries and their respective officers, directors, agents and employees with each of the following
laws:&nbsp;anti-bribery laws, including but not limited to, any applicable law, rule, or regulation of any locality, including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery of
Foreign Public Officials in International Business Transactions, signed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
December 17, 1997, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule or regulation of similar purposes and scope, or
anti-money laundering laws, including but not limited to, applicable federal, state, international, foreign or other laws, regulations or government guidance regarding anti-money laundering, including, without limitation, Title 18 US. Code section
1956 and 1957, the Patriot Act, the Bank Secrecy Act, and international anti-money laundering principles or procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money Laundering, of which the United
States is a member and with which designation the United States representative to the group or organization continues to concur, all as amended, and any Executive order, directive, or regulation pursuant to the authority of any of the foregoing, or
any orders or licenses issued thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xxix)&nbsp;<I><U>OFAC</U></I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(A) Neither the Company nor any of its subsidiaries nor, to the Company&#146;s knowledge, any of their directors, officers,
employees, agents, affiliates or representatives, is an individual or entity that is, or is owned or controlled by an individual or entity that is: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) the subject of any sanctions administered or enforced by the U.S. Department of Treasury&#146;s Office of Foreign Assets
Control, the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury, or other relevant sanctions authority (collectively, <B><I>&#147;Sanctions&#148;</I></B>), nor </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) located, organized or resident in a country or territory that is the subject of Sanctions (including, without limitation,
Burma/Myanmar, Cuba, Iran, Libya, North Korea, Sudan and Syria). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(B) Neither the Company nor any of its subsidiaries will,
directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other individual or entity: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) to fund or facilitate any activities or business of or with any individual or entity or in any country or territory that,
at the time of such funding or facilitation, is the subject of Sanctions; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) in any other manner that will result in
a violation of Sanctions by any individual or entity (including any individual or entity participating in the offering, whether as underwriter, advisor, investor or otherwise). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(C) For the past five years, neither the Company nor any of its subsidiaries has knowingly engaged in, and is not now knowingly
engaged in, any dealings or transactions with any individual or entity, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xxx) <I><U>Compliance with Environmental Laws</U></I>.&nbsp;Except as disclosed
in the Time of Disclosure Package and the Prospectuses, neither the Company nor any of its subsidiaries is in violation of any statute, rule, regulation, decision or order of any Governmental Authority or any court, domestic or foreign, relating to
the use, disposal or release of hazardous or toxic substances or relating to the protection or restoration of the environment or human exposure to hazardous or toxic substances (collectively, <B><I>&#147;Environmental Laws&#148;</I></B>), owns or
operates any real property contaminated with any substance that is subject to any Environmental Laws, is liable for any off-site disposal or contamination pursuant to any Environmental Laws, or is subject to any claim relating to any Environmental
Laws, which violation, contamination,&nbsp;liability or claim would reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; and the Company is not aware of any pending investigation which would reasonably be
expected to lead to such a claim.&nbsp;Neither the Company nor any of its subsidiaries anticipates incurring any material capital expenditures relating to compliance with Environmental Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xxxi) <I><U>Compliance with Occupational Laws</U></I>.&nbsp;The Company and each of its subsidiaries (A) is in compliance, in
all material respects, with any and all applicable foreign, federal, state and local laws, rules, regulations, treaties, statutes and codes promulgated by any and all Governmental Authorities (including pursuant to the Occupational Health and Safety
Act) relating to the protection of human health and safety in the workplace (<B><I>&#147;Occupational Laws&#148;</I></B>); (B) has received all material permits, licenses or other approvals required of it under applicable Occupational Laws to
conduct its business as currently conducted; and (C) is in compliance with all terms and conditions of such permit, license or approval except where the failure to be in compliance or receive such permits or licenses would not reasonably be expected
to have a Material Adverse Effect.&nbsp;No action, proceeding, revocation proceeding, writ, injunction or claim is pending or, to the Company&#146;s knowledge, threatened against the Company or any of its subsidiaries relating to Occupational Laws,
and the Company does not have knowledge of any facts, circumstances or developments relating to its operations or cost accounting practices that would reasonably be expected to form the basis for or give rise to such actions, suits, investigations
or proceedings. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xxxii) <I><U>Regulatory Matters</U></I><I>. </I>All preclinical studies and clinical trials conducted by
or on behalf of the Company and its subsidiaries that are material to the Company and its subsidiaries, taken as a whole, have been adequately described in the Registration Statements, the Time of Sale Disclosure Package and the Prospectuses in all
material respects. The preclinical studies and clinical trials conducted by or on behalf of the Company were and, if still ongoing, are being conducted in material compliance with all laws and regulations applicable thereto in the jurisdictions in
which they are being conducted and with all laws and regulations applicable to preclinical studies and clinical trials from which data will be submitted to support marketing approval. The descriptions in the Registration Statements, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Time of Sale Disclosure Package and the Prospectuses of the results of such studies and trials are accurate and complete in all material respects and fairly present the data derived from such
studies, and the Company has no knowledge of any large well-controlled clinical trial the aggregate results of which call into question the results of any clinical trial conducted by or on behalf of the Company that are described in the Registration
Statements, the Time of Disclosure Package and the Prospectuses or the results of which are referred to in the Registration Statements, the Time of Sale Disclosure Package and the Prospectuses. Except as disclosed in the Registration Statements, the
Time of Sale Disclosure Package and the Prospectuses, the Company has not received any notices or statements from the U.S. Food and Drug Administration <B>(</B><B><I>&#147;FDA&#148;</I></B>), the European Medicines Agency
(<B><I>&#147;EMA&#148;</I></B>) or any comparable regulatory agency (each a <B><I>&#147;Regulatory Authority&#148;</I></B>) imposing, requiring, requesting or suggesting a clinical hold, termination, suspension or material modification for or of any
preclinical studies or clinical trials that are described in the Registration Statements, the Time of Sale Disclosure Package and the Prospectuses or the results of which are referred to in the Registration Statements, the Time of Sale Disclosure
Package and the Prospectuses. Except as disclosed in the Registration Statements, the Time of Sale Disclosure Package and the Prospectuses, the Company has not received any notices or statements from any Regulatory Authority, and otherwise has no
knowledge of (A) any investigational new drug application for any potential product of the Company is or has been rejected or determined to be non-approvable or conditionally approvable; and (B) any license, approval, permit or authorization to
conduct any clinical trial of any potential product of the Company has been, will be or may be suspended, revoked, materially modified or materially limited. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xxxiii) <I><U>Authorizations; Permits</U></I><I>. </I>The Company and each of its subsidiaries: (A) are in compliance in all
material respects with all statutes, rules, or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, labeling, storage, import, export or disposal of any product manufactured or
distributed by the Company (<B><I>&#147;Applicable Laws&#148;</I></B>); (B) have not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from any Regulatory Authority alleging or
asserting noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (<B><I>&#147;Authorizations&#148;</I></B>); (C)
possess all Authorizations and such Authorizations are valid and in full force and effect and are not in violation of any material term of any such Authorizations; (D) have not received notice of any claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action from any Governmental Authority or third party alleging that any product operation or activity is in violation in any material respect of any Applicable Laws or Authorizations and, to the
knowledge of the Company, no such proceedings are threatened or contemplated by any such Governmental Authority or third party; (E) have not received notice that any Regulatory Authority has taken, is taking or will take action to limit, suspend,
modify </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or revoke in any material respect any Authorizations and, to the knowledge of the Company, no such Regulatory Authority has threatened such action; and (F) have filed, obtained, maintained or
submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such material reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments were complete and correct in all material respects on the date filed (or were corrected or supplemented by a subsequent submission). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xxxiv) <I><U>Statistical Information</U></I><I>. </I>Any Company-derived statistical and market-related data included in the
Time of Sale Disclosure Package and Prospectuses have been derived from the records of the Company using systems and procedures which incorporate adequate safeguards to ensure that the data are complete, true and accurate in all material respects
and are not misleading; any third-party statistical and market-related data included in the Time of Sale Disclosure Package and Prospectuses are based on or derived from sources that the Company reasonably believes to be reliable and accurate, and
the Company has obtained the written consent for the use of such data from such sources to the extent required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xxxv)
<I><U>ERISA and Employee Benefits Matters</U></I>. (A) To the knowledge of the Company, no &#147;prohibited transaction&#148; as defined under Section 406 of ERISA or Section 4975 of the Code and not exempt under ERISA Section 408 and the
regulations and published interpretations thereunder has occurred with respect to any Employee Benefit Plan.&nbsp;At no time has the Company or any ERISA Affiliate maintained, sponsored, participated in, contributed to or has or had any liability or
obligation in respect of any Employee Benefit Plan subject to Part 3 of Subtitle B of Title I of ERISA, Title IV of ERISA, or Section 412 of the Code or any &#147;multiemployer plan&#148; as defined in Section 3(37) of ERISA or any multiple employer
plan for which the Company or any ERISA Affiliate has incurred or could incur liability under Section 4063 or 4064 of ERISA.&nbsp;No Employee Benefit Plan provides or promises retiree health, life insurance, or other retiree welfare benefits except
as may be required by the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, or similar state law.&nbsp;Each Employee Benefit Plan is operated in material compliance with its terms and all applicable laws, including but not limited
to ERISA and the Code and, to the knowledge of the Company, no event has occurred (including a &#147;reportable event&#148; as such term is defined in Section 4043 of ERISA) and no condition exists that would reasonably be expected to subject the
Company or any ERISA Affiliate to any material tax, fine, lien, penalty or liability imposed by ERISA, the Code or other applicable law.&nbsp;Each Employee Benefit Plan intended to be qualified under Code Section 401(a) is so qualified and has a
favorable determination or opinion letter from the IRS upon which it can rely, and any such determination or opinion letter remains in effect and has not been revoked; to the knowledge of the Company, nothing has occurred since the date of any such
determination or opinion letter that is reasonably likely to adversely affect such qualification; (B) with respect to each Foreign Benefit Plan, such Foreign Benefit Plan (1) if intended to qualify for special tax treatment, meets, in all material
respects, the requirements for such treatment, and (2) if required to be funded, is funded to the extent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
required by applicable law, and with respect to all other Foreign Benefit Plans, adequate reserves therefor have been established on the accounting statements of the applicable Company or
subsidiary; (C) the Company does not have any obligations under any collective bargaining agreement with any union and no organization efforts are underway with respect to Company employees.&nbsp;As used in this Agreement,
<B><I>&#147;Code&#148;</I></B> means the Internal Revenue Code of 1986, as amended; <B><I>&#147;Employee Benefit Plan&#148;</I></B> means any &#147;employee benefit plan&#148; within the meaning of Section 3(3) of ERISA, including, without
limitation, all stock purchase, stock option, stock-based severance, employment, change-in-control, medical, disability, fringe benefit, bonus, incentive, deferred compensation, employee loan and all other employee benefit plans, agreements,
programs, policies or other arrangements, whether or not subject to ERISA, under which (1) any current or former employee, director or independent contractor of the Company or any subsidiary has any present or future right to benefits and which are
contributed to, sponsored by or maintained by the Company or any subsidiary or (2) the Company or any subsidiary has had or has any present or future obligation or liability; <B><I>&#147;ERISA&#148;</I></B> means the Employee Retirement Income
Security Act of 1974, as amended; <B><I>&#147;ERISA Affiliate&#148; </I></B>means any member of the company&#146;s controlled group as defined in Code Section 414(b), (c), (m) or (o); and <B><I>&#147;Foreign Benefit Plan&#148;</I></B> means any
Employee Benefit Plan established, maintained or contributed to outside of the United States of America or which covers any employee working or residing outside of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xxxvi)&nbsp;<I><U>Business Arrangements</U></I>.&nbsp;Except as disclosed in the Registration Statements, the Time of Sale
Disclosure Package and the Prospectuses, neither the Company nor any subsidiary has granted rights to develop, manufacture, produce, assemble, distribute, license, market or sell its products to any other person and is not bound by any agreement
that affects the exclusive right of the Company or such subsidiary to develop, manufacture, produce, assemble, distribute, license, market or sell its products. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xxxvii)&nbsp;<I><U>Labor Matters</U></I>.&nbsp;No material labor problem or dispute with the employees of the Company or any
subsidiary exists or, to the knowledge of the Company, is threatened or imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or its subsidiaries&#146; principal suppliers, contractors or
customers, that would reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xxxviii)&nbsp;<I><U>Restrictions on
Subsidiary Payments to the Company</U></I>.&nbsp;No subsidiary of the Company is currently prohibited, directly or indirectly, from paying any dividends to the Company, from making any other distribution on such subsidiary&#146;s capital stock, from
repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#146;s property or assets to the Company or any other subsidiary of the Company, except as described in or contemplated by
the Time of Sale Disclosure Package and the Prospectuses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xxxix)&nbsp;<I><U>Forward-looking Statements</U></I>.&nbsp;No
forward-looking statement (within the meaning of Section 27A of the Act and Section 21E of the Exchange Act) contained in the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable
basis or has been disclosed other than in good faith. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <I><U>Representations and Warranties of the Selling Stockholder</U></I>.&nbsp;The Selling
Stockholders represent and warrant to, and agree, severally, with, the several Underwriters as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <I><U>Delivery
of Securities</U></I>.&nbsp;On each of the First Closing Date and the Second Closing Date, each Selling Stockholder will have good and valid title to or a valid &#147;security entitlement&#148; within the meaning of Section 8-501 of the New York
Uniform Commercial Code (the <B><I>&#147;UCC&#148;</I></B>) in respect of, the Securities to be sold by such Selling Stockholder hereunder on such date, free and clear of all liens, encumbrances, equities or claims. Upon payment for the Securities
to be sold by such Selling Stockholder, delivery of such Securities, as directed by the Representative, to Cede &amp; Co. (<B><I>&#147;Cede&#148;</I></B>) or such other nominee as may be designated by The Depository Trust Company
(<B><I>&#147;DTC&#148;</I></B>), registration of such Securities in the name of Cede or such other nominee and the crediting of such Securities on the books of DTC to securities accounts of the Underwriters (assuming that neither DTC nor any such
Underwriter has notice of any adverse claim (within the meaning of Section 8-105 of the UCC) to such Securities), (A) DTC will be a &#147;protected purchaser&#148; of the Securities within the meaning of Section 8-303 of the UCC, (B) under Section
8-501 of the UCC, the Underwriters will acquire a valid security entitlement in respect of such Securities and (C) no action based on any valid &#147;adverse claim,&#148; within the meaning of Section 8-102 of the UCC, to such Securities may be
asserted against the Underwriters with respect to such security entitlement. For purposes of this representation, each Selling Stockholder may assume that when such payment, delivery and crediting occur, (x) such Securities will have been registered
in the name of Cede or another nominee designated by DTC, in each case on the Company&#146;s share registry in accordance with its certificate of incorporation, bylaws and applicable law, (y) DTC will be registered as a &#147;clearing
corporation&#148; within the meaning of Section 8-102 of the UCC and (z) appropriate entries to the accounts of the several Underwriters on the records of DTC will have been made pursuant to the UCC.</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) <I><U>Reserved</U></I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) <I><U>Reserved</U></I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) <I><U>Authorization; No Conflicts; Authority</U></I>.&nbsp;This Agreement has been duly authorized, executed and delivered
by or on behalf of each Selling Stockholder and constitutes a valid and binding agreement of such Selling Stockholder, enforceable in accordance with its terms, except as rights to indemnity hereunder or thereunder may be limited by federal or state
securities laws and except as such enforceability may be limited by bankruptcy, insolvency, reorganization or laws affecting the rights of creditors generally and subject to general principles of equity.&nbsp;The execution and delivery of this
Agreement and the performance of the terms hereof and the consummation of the transactions herein contemplated will not (A) conflict with or result in a breach or violation of any of the terms </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or provisions of, or constitute a default under, any agreement or instrument to which such Selling Stockholder is a party or by which such Selling Stockholder is bound, (B) result in any
violation of the provisions of such Selling Stockholder&#146;s charter or by-laws (or similar organizational documents) or (C) result in the violation of any law, regulation, order or decree applicable to such Selling Stockholder; no consent,
approval, authorization or order of, or filing with, any court or governmental agency or body is required for the execution, delivery and performance of this Agreement or for the consummation of the transactions contemplated hereby, including the
sale of the Securities being sold by such Selling Stockholder, except such as may be required under the Securities Act or state securities laws or blue sky laws or the rules of FINRA.&nbsp;Each Selling Stockholder has full power and authority to
enter into this Agreement and to consummate the transactions contemplated hereby, including to sell, assign, transfer and deliver the Securities to be sold by such Selling Stockholder hereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) <I><U>Registration Rights</U></I>.&nbsp;Such Selling Stockholder does not have any registration or other similar rights to
have any equity or debt securities registered for sale by the Company under the Registration Statement or included in the offering contemplated by this Agreement, except as described or incorporated by reference in the Registration Statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vi) <I><U>No Other Offering Materials</U></I>.&nbsp;No Selling Stockholder has distributed and no Selling Stockholder will
distribute, any prospectus or other offering material in connection with the offering and sale of the Securities other than any Preliminary Prospectuses, the Time of Sale Disclosure Package or the Prospectuses or other materials permitted by the
Securities Act to be distributed by such Selling Stockholder; <I>provided, however,</I> that such&nbsp;Selling Stockholder has not made nor will make any offer relating to the Securities that would constitute a free writing prospectus except a
Permitted Free Writing Prospectus (as defined below) authorized by the Company and the Underwriters for distribution in accordance with the provisions of Section 4(a)(xv) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vii) <I><U>Accurate Disclosure; Compliance with the Act</U></I>.&nbsp;Neither the Registration Statements nor any amendment
thereto, at the effective time of each part thereof,&nbsp;contained or will contain an untrue statement of a material fact or omitted or will omit to state a material fact required to be stated therein or necessary to make the statements therein not
misleading. As of the Time of Sale, neither (A) the Time of Sale Disclosure Package nor (B) any issuer free writing prospectus, when considered together with the Time of Sale Disclosure Package, included an untrue statement of a material fact or
omitted to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. Neither the Prospectus nor supplement thereto, as of its issue date, at the time of any
filing with the Commission pursuant to Rule 424(b) of the Rules and Regulations, at the First Closing Date or at the Second Closing, included, includes or will include an untrue statement of a material fact or omitted, omits or will omit to state a
material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.&nbsp;As of the time each part of the Registration Statement (or any post effective amendment thereto) became
or becomes effective, such part conformed or will conform in all material respects </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
to the requirements of the Act and the Rules and Regulations.&nbsp;Upon the filing or first use within the meaning of the Rules and Regulations, each Preliminary Prospectus and the Prospectus (or
any supplement to either) conformed or will conform in all material respects to the requirements of the Act and the Rules and Regulations.&nbsp;The representations and warranties in this Section 2(b)(vii) with respect to any Selling Stockholder
apply only to the extent that any statements in or omissions from any such document are based on information covering such Selling Stockholder furnished to the Company by such Selling Stockholder specifically for use therein (any written information
concerning such Selling Stockholder specifically for such use being referred to as the <B><I>&#147;Selling Stockholder Information&#148;</I></B>). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(viii) <I><U>Selling Stockholder Information in Issuer Free Writing Prospectuses</U></I>.&nbsp;All Selling Stockholder
Information furnished by a Selling Stockholder for inclusion in any issuer free writing prospectus does not include any information that conflicts with the information then contained in the Registration Statements, any Preliminary Prospectus or the
Prospectuses.&nbsp;If at any time following issuance of an issuer free writing prospectus there occurred or occurs an event or development as a result of which such Selling Stockholder Information, if republished immediately following such event or
development, conflicted or would conflict with the information then contained in any such document or as a result of which such Selling Stockholder Information would include any untrue statement of a material fact or omitted or would omit to state a
material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, such Selling Stockholder has promptly notified or will promptly notify the Company and Piper Jaffray &amp;
Co. and will provide the Company with all necessary information so as to correct such untrue statement or omission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ix)
<I><U>No Inside Information</U></I>.&nbsp;The sale of the Securities by each Selling Stockholder pursuant to this Agreement is not prompted by any material information concerning the Company or any of its subsidiaries that is not set forth in the
Time of Disclosure Package and Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(x) <I><U>No FINRA Member Affiliation</U></I>.&nbsp;Neither any Selling
Stockholder nor any of his, her or its affiliates directly, or indirectly through one or more intermediaries, controls, or is controlled by, or is under common control with any member firm of FINRA or is a person associated with a member (within the
meaning of the FINRA By-Laws) of FINRA. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <I><U>Effect of Certificates</U></I>.&nbsp;Any certificate signed by any officer of the
Company and delivered to you or to counsel for the Underwriters shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered thereby; any certificate signed by or on behalf of a Selling Stockholder as
such and delivered to you or to counsel for the Underwriters shall be deemed a representation and warranty by such Selling Stockholder to each Underwriter as to the matters covered thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B><I>Purchase, Sale and Delivery of Securities</I></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <I><U>Firm Shares</U></I>. On the basis of the representations, warranties and agreements herein contained, but subject to the terms and
conditions herein set forth, the Company agrees to issue and sell the Firm Shares, and the Selling Stockholders agree, to sell the number of Firm Shares set forth opposite the name of each Selling Stockholder in Schedule I hereto, to the several
Underwriters, and each Underwriter agrees, severally and not jointly, to purchase from the Company and each Selling Stockholder the number of Firm Shares set forth opposite the name of such Underwriter in <U>Schedule II</U> hereto.&nbsp;The purchase
price for each Firm Share shall be $3.76 per share.&nbsp;The obligation of each Underwriter to each of the Company and each Selling Stockholder shall be to purchase from each of the Company and such Selling Stockholder that number of Firm Shares (to
be adjusted by the Representative to avoid fractional shares) which represents the same proportion of the number of Firm Shares to be sold by each of the Company and such Selling Stockholder pursuant to this Agreement as the number of Firm Shares
set forth opposite the name of such Underwriter in <U>Schedule II</U> hereto represents to the total number of Firm Shares to be purchased by all Underwriters pursuant to this Agreement.&nbsp;In making this Agreement, each Underwriter is contracting
severally and not jointly; except as provided in paragraph (c) of this Section 3 and in Section 8 hereof, the agreement of each Underwriter is to purchase only the respective number of Firm Shares specified in <U>Schedule II</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Firm Shares will be delivered by the Company and the Custodian to you for the accounts of the several Underwriters against payment of the
purchase price therefor by wire transfer of same day funds payable to the order of the Company and the Custodian, as appropriate, at the offices of Piper Jaffray &amp; Co., U.S. Bancorp Center, 800 Nicollet Mall, Minneapolis, Minnesota, or such
other location as may be mutually acceptable, at 9:00 a.m. Central time on the third (or if the Securities are priced, as contemplated by Rule 15c6-1(c) under the Exchange Act, after 4:30 p.m. Eastern time, the fourth) full business day following
the date hereof, or at such other time and date as you and the Company determine pursuant to Rule 15c6-1(a) under the Exchange Act, such time and date of delivery being herein referred to as the <B><I>&#147;First Closing Date.&#148;</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <I><U>Option Shares</U></I>.&nbsp;On the basis of the representations, warranties and agreements herein contained, but subject to the terms
and conditions herein set forth, the Company, with respect to 225,000 of the Option Shares, and each Selling Stockholder, with respect to the number of Option Shares set forth opposite the name of such Selling Stockholder in Schedule I hereto,
hereby grant to the several Underwriters an option to purchase all or any portion of the Option Shares at the same purchase price as the Firm Shares, for use solely in covering any over-allotments made by the Underwriters in the sale and
distribution of the Firm Shares.&nbsp;The option granted hereunder may be exercised in whole or in part at any time (but not more than once) within 30 days after the effective date of this Agreement upon notice (confirmed in writing) by the
Representative to the Company and to the Attorneys-in-Fact setting forth the aggregate number of Option Shares as to which the several Underwriters are exercising the option, the names and denominations in which the certificates for the Option
Shares are to be registered and the date and time, as determined by you, when the Option Shares are to be delivered, such time and date being herein referred to as the <B><I>&#147;Second Closing&#148;</I></B> and <B><I>&#147;Second Closing
Date&#148;</I></B>, respectively; provided, however, that the Second Closing Date shall not be earlier than the First Closing Date nor earlier than the second business day after the date on which the option shall have been exercised.&nbsp;If the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
option is exercised, the obligation of each Underwriter shall be to purchase from each Selling Stockholder granting an option to purchase the Option Shares, on a pro rata basis up to 225,000
Option Shares, that number of Option Shares (to be adjusted by the Representative to avoid fractional shares) which represents the same proportion that the number of Option Shares granted by each such Selling Stockholder bears to the total number of
Option Shares granted by all such Selling Stockholder, and, to the extent the option to purchase Option Shares exceeds 225,000, from the Company up to an aggregate of 225,000 Option Shares.&nbsp;The number of Option Shares to be purchased by each
Underwriter shall be the same percentage of the total number of Option Shares to be purchased by the several Underwriters as the number of Firm Shares to be purchased by such Underwriter is of the total number of Firm Shares to be purchased by the
several Underwriters, as adjusted by the Representative in such manner as the Representative deem advisable to avoid fractional shares.&nbsp;No Option Shares shall be sold and delivered unless the Firm Shares previously have been, or simultaneously
are, sold and delivered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Option Shares will be delivered by the Custodian and the Company, as appropriate, to you for the accounts of
the several Underwriters against payment of the purchase price therefor by wire transfer of same day funds payable to the order of the Custodian or the Company, as appropriate, at the offices of Piper Jaffray &amp; Co., U.S. Bancorp Center, 800
Nicollet Mall, Minneapolis, Minnesota, or such other location as may be mutually acceptable at 9:00 a.m., Central time, on the Second Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <I><U>Delivery</U></I>.&nbsp;If the Representative so elects, delivery of the Firm Shares or the Option Shares may be made by credit
through full fast transfer to the accounts at DTC designated by the Representative.&nbsp;Certificates representing the Firm Shares and the Option Shares in definitive form and in such denominations and registered in such names as you have set forth
in your notice of option exercise, or evidence of their issuance, will be made available for checking at a reasonable time preceding the First Closing Date or the Second Closing Date, as applicable, at the office of Piper Jaffray &amp; Co., 800
Nicollet Mall, Minneapolis, Minnesota, or such other location as may be mutually acceptable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <I><U>Purchase by Representative on
Behalf of Underwriters</U></I>.&nbsp;It is understood that you, individually and not as Representative of the several Underwriters, may (but shall not be obligated to) make payment to the Company or any Selling Stockholder, on behalf of any
Underwriter for the Securities to be purchased by such Underwriter.&nbsp;Any such payment by you shall not relieve any such Underwriter of any of its obligations hereunder.&nbsp;Nothing herein contained shall constitute any of the Underwriters an
unincorporated association or partner with the Company or any Selling Stockholder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B><I>Covenants</I></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <I><U>Covenants of the Company</U></I>. The Company covenants and agrees with the several Underwriters as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <I><U>Required Filings</U></I>.&nbsp;During the period beginning on the date hereof and ending on the later of the Second
Closing Date or such date, as in the opinion of counsel for the Underwriters, the Prospectuses are no longer required by law to be delivered (assuming the absence of Rule 172 under the Securities Act), in connection with sales by an Underwriter or
dealer (the <B>&#147;</B><B><I>Prospectus Delivery Period&#148;</I></B>), prior to amending or supplementing the Registration Statements, including any Rule 462(b) Registration Statement), the Time of Sale Disclosure Package or the Prospectuses, the
Company shall furnish to the Representative for review a copy of each such proposed amendment or supplement, and the Company shall not file any such proposed amendment or supplement to which the Representative or counsel to the Underwriters
reasonably object.&nbsp;Subject to this Section 4(a)(i), immediately following execution of this Agreement, the Company will prepare the Prospectuses containing the Rule 430B Information and other selling terms of the Securities, the plan of
distribution thereof and such other information as may be required by the Securities Act or the Rules and Regulations or as the Representative and the Company may deem appropriate, and if requested by the Representative, an issuer free writing
prospectus containing the selling terms of the Securities and such other information as the Company and the Representative may deem appropriate, and will file or transmit for filing with the Commission, in accordance with Rule 424(b) or Rule 433, as
the case may be, copies of the Prospectuses and each issuer free writing prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) <I><U>Notification of Certain
Commission Actions</U></I>.&nbsp;After the date of this Agreement, the Company shall promptly advise the Representative in writing (A) of the receipt of any comments of, or requests for additional or supplemental information from, the Commission,
(B) of the time and date of any filing of any post-effective amendment to the Registration Statements or any amendment or supplement to any Preliminary Prospectuses, the Time of Sale Disclosure Package or the Prospectuses, (C) of the time and date
that any post-effective amendment to the Registration Statements become effective, (D) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statements or any post-effective amendments thereto or of any
order preventing or suspending its use or the use of any Preliminary Prospectuses, the Time of Sale Disclosure Package, the Prospectuses or any issuer free writing prospectus, or (E) of any proceedings to remove, suspend or terminate from listing or
quotation the Common Stock from any securities exchange upon which it is listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such purposes.&nbsp;If the Commission shall enter
any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order at the earliest possible moment.&nbsp;Additionally, the Company agrees that it shall comply with the provisions of Rules 424(b), 430A and
430B, as applicable, under the Securities Act and will use its commercially reasonable efforts to confirm that any filings made by the Company under Rule 424(b), Rule 433 or Rule 462 were received in a timely manner by the Commission (without
reliance on Rule 424(b)(8) or Rule 164(b)). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) <I><U>Continued Compliance with Securities
Laws</U></I>.&nbsp;(A)&nbsp;During the Prospectus Delivery Period, the Company will comply to the extent it is able with all requirements imposed upon it by the Securities Act, as now and hereafter amended, and by the Rules and Regulations, as from
time to time in force, and by the Exchange Act so far as necessary to permit the continuance of sales of or dealings in the Securities as contemplated by the provisions hereof, the Time of Sale Disclosure Package and the Prospectuses.&nbsp;If during
the Prospectus Delivery Period any event occurs as a result of which the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-23- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Prospectuses (or if the Prospectuses are not yet available to prospective purchasers, the Time of Sale Disclosure Package) would include an untrue statement of a material fact or omit to state a
material fact necessary to make the statements therein, in the light of the circumstances then existing, not misleading, or if during the Prospectus Delivery Period it is necessary or appropriate in the opinion of the Company or its counsel or the
Representative or counsel to the Underwriters to amend the Registration Statements or supplement the Prospectuses (or, if the Prospectuses are not yet available to prospective purchasers, the Time of Sale Disclosure Package) to comply with the
Securities Act or to file under the Exchange Act any document which would be deemed to be incorporated by reference in the Prospectuses in order to comply with the Securities Act or the Exchange Act, the Company promptly will (x) notify you of such
untrue statement or omission, (y)&nbsp;amend the Registration Statement or supplement the Prospectus (or, if the Prospectus is not yet available to prospective purchasers, the Time of Sale Disclosure Package) or file such document (at the expense of
the Company) so as to correct such statement or omission or effect such compliance, and (z) notify you when any amendment to the Registration Statements are filed or becomes effective or when any supplement to the Prospectuses (or, if the
Prospectuses are not yet available to prospective purchasers, the Time of Sale Disclosure Package) is filed.</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(B) If at any
time following issuance of an issuer free writing prospectus there occurred or occurs an event or development as a result of which such issuer free writing prospectus conflicted or would conflict with the information contained in the Registration
Statements, the Preliminary Prospectuses or the Prospectuses or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances prevailing at that subsequent time, not misleading, the Company (x) promptly will notify the Representative of such conflict, untrue statement or omission, (y) promptly will amend or supplement, at its own expense, such issuer free
writing prospectus to eliminate or correct such conflict, untrue statement or omission, and (2) promptly will notify you when such amendment or supplement was or is filed with the Commission where so required to be filed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(C) If immediately prior to the third anniversary of the initial effective date of the Registration Statements, any of the
Securities remain unsold by the Underwriters, the Company will prior to that third anniversary file, if it has not already done so, a new shelf registration statement relating to the Securities, in a form satisfactory to the Representative, will use
its commercially reasonable efforts to cause such registration statement to be declared effective within 180 days after that third anniversary, and will take all other action reasonably necessary or appropriate to permit the public offering and sale
of the Securities to continue as contemplated in the expired registration statement relating to the Securities.&nbsp;References herein to the Registration Statements shall include such new shelf registration statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-24- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) <I><U>Blue Sky Qualifications</U></I>.&nbsp;The Company shall take or cause
to be taken all reasonably necessary action to qualify the Securities for sale under the securities laws of such jurisdictions as you reasonably designate and to continue such qualifications in effect so long as required for the distribution of the
Securities, except that the Company shall not be required in connection therewith to qualify as a foreign corporation or to execute a general consent to service of process in any state. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) <I><U>Provision of Documents</U></I>.&nbsp;The Company will furnish, at its own expense, to the Underwriters and counsel
for the Underwriters copies of the Registration Statements (which will include three complete manually signed copies of the Registration Statements and all consents and exhibits filed therewith), and to the Underwriters and any dealer each
Preliminary Prospectuses, the Time of Sale Disclosure Package, the Prospectuses, any issuer free writing prospectus, and all amendments and supplements to such documents, in each case as soon as available and in such quantities as you may from time
to time reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vi) <I><U>Rule 158</U></I>.&nbsp;The Company will make generally available to its security
holders as soon as practicable, but in no event later than 15 months after the end of the Company&#146;s current fiscal quarter, an earnings statement (which need not be audited) covering a 12-month period that shall satisfy the provisions of
Section 11(a) of the Securities Act and Rule 158 of the Rules and Regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vii) <I><U>Payment and Reimbursement of
Expenses</U></I>.&nbsp;The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, will pay or cause to be paid&nbsp;(A) all expenses (including transfer taxes allocated to the respective
transferees) incurred in connection with the delivery to the Underwriters of the Securities, (B) all expenses and fees (including, without limitation, fees and expenses of the Company&#146;s accountants and counsel but, except as otherwise provided
below, not including fees of the Underwriters&#146; counsel) in connection with the preparation, printing, filing, delivery, and shipping of the Registration Statements (including the financial statements therein and all amendments, schedules, and
exhibits thereto), the Securities, each Preliminary Prospectus, the Time of Sale Disclosure Package, the Prospectuses, any issuer free writing prospectus and any amendment thereof or supplement thereto, and the printing, delivery, and shipping of
this Agreement and other underwriting documents, including Blue Sky Memoranda (covering the states and other applicable jurisdictions), (C) all filing fees and fees and disbursements of the Underwriters&#146; counsel incurred in connection with the
qualification of the Securities for offering and sale by the Underwriters or by dealers under the securities or blue sky laws of the states and other jurisdictions which you shall designate, (D) the fees and expenses of the Custodian and any
transfer agent or registrar, (E) the filing fees and fees and disbursements of Underwriters&#146; counsel incident to any required review and approval by FINRA of the terms of the sale of the Securities, (F) listing fees, if any, (G) the cost and
expenses of the Company relating to investor presentations or any &#147;roadshow&#148; undertaken in connection with marketing of the Securities and&nbsp;(H) all other costs and expenses of the Company incident to the performance of its obligations
hereunder that are not otherwise specifically provided for herein. The Company and the Selling Stockholders will pay, all other reasonable fees of Underwriters&#146; counsel incurred in connection with the transactions contemplated by this
Agreement, in an amount not to exceed $125,000, with the Company and each Selling Stockholder paying such portion of the $125,000 in the same proportion that the number of Securities sold by such party (including any Option Shares) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-25- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">bears to the total number of Securities sold hereunder.&nbsp;If this Agreement is terminated by
the Representative pursuant to Section 9 hereof or if the sale of the Securities provided for herein is not consummated by reason of any failure, refusal or inability on the part of the Company or any Selling Stockholder to perform any agreement on
its or their part to be performed, or because any other condition of the Underwriters&#146; obligations hereunder required to be fulfilled by the Company or any Selling Stockholder is not fulfilled, the Company or such Selling Stockholder, as the
case may be, will reimburse the several Underwriters for all out-of-pocket accountable disbursements (including but not limited to fees and disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone charges)
incurred by the Underwriters in connection with their investigation, preparing to market and marketing the Securities or in contemplation of performing their obligations hereunder; <I>provided however</I>, if the sale of the Securities provided for
herein is not consummated by reason of any failure, refusal or inability on the part of both the and any or all the Selling Stockholders to perform any agreement on their part to be performed, then such reimbursement shall be paid by the defaulting
parties in proportion to the number of Securities to be sold by such party (including any Option Shares) bears to the total number of Securities sold by all such defaulting parties.</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(viii) <I><U>Use of Proceeds</U></I>.&nbsp;The Company will apply the net proceeds from the sale of the Securities to be sold
by it hereunder for the purposes set forth in the Time of Sale Disclosure Package and in the Prospectuses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ix)
<I><U>Company Lock Up</U></I>.&nbsp;The Company will not, without the prior written consent of Piper Jaffray &amp; Co., from the date of execution of this Agreement and continuing to and including the date 90 days after the date of the Prospectus
(the <B><I>&#147;Lock-Up Period&#148;</I></B>), (A) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to
purchase or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or (B) enter into any swap or other agreement that transfers, in
whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause (A) or (B) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise,
except to the Underwriters pursuant to this Agreement and except pursuant to any Company Stock Plan.&nbsp;The Company agrees not to accelerate the vesting of any option or warrant or the lapse of any repurchase right prior to the expiration of the
Lock-Up Period. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(x) <I><U>Stockholder Lock-Ups</U></I>.&nbsp;The Company has caused to be delivered to you prior to the
date of this Agreement a letter, in the form of Exhibit A hereto (the <B><I>&#147;Lock-Up Agreement&#148;</I></B>), from each individual or entity listed on <U>Schedule V</U>I.&nbsp;The Company will enforce the terms of each Lock-Up Agreement and
issue stop-transfer instructions to the transfer agent for the Common Stock with respect to any transaction or contemplated transaction that would constitute a breach of or default under the applicable Lock-Up Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-26- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xi) <I><U>No Market Stabilization or Manipulation</U></I>.&nbsp;The Company has
not taken and will not take, directly or indirectly, any action designed to or which might reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of the Securities </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xii) <I><U>SEC Reports</U></I>.&nbsp;During the Prospectus Delivery
Period, the Company will file on a timely basis with the Commission such periodic and special reports as required by the Rules and Regulations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii) <I><U>Internal Controls</U></I>.&nbsp;The Company and its subsidiaries will maintain such controls and other procedures,
including without limitation those required by Sections 302 and 906 of the Sarbanes-Oxley Act and the applicable regulations thereunder, that are designed to ensure that information required to be disclosed by the Company in the reports that it
files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#146;s rules and forms, including without limitation, controls and procedures designed to ensure that
information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&#146;s management, including its principal executive officer and its principal
financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure, to ensure that material information relating to Company, including its subsidiaries, is made known to them by others
within those entities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xiv) <I><U>Sarbanes-Oxley</U></I>.&nbsp;The Company and its subsidiaries will comply with all
applicable provisions of the Sarbanes-Oxley Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xv) <I><U>Free Writing Prospectuses</U></I>.&nbsp;The Company represents
and agrees that, unless it obtains the prior written consent of Piper Jaffray &amp; Co., and each Underwriter severally represents and agrees that, unless it obtains the prior written consent of the Company and Piper Jaffray &amp; Co., it has not
made and will not make any offer relating to the Securities that would constitute an issuer free writing prospectus or that would otherwise constitute a free writing prospectus required to be filed with the Commission; provided that the prior
written consent of the parties hereto shall be deemed to have been given in respect of the free writing prospectuses included in <U>Schedule III</U>. Any such free writing prospectus consented to by the Company and Piper Jaffray &amp; Co. is
hereinafter referred to as a <B><I>&#147;Permitted Free Writing Prospectus.&#148;</I></B>&nbsp;The Company represents that it has treated or agrees that it will treat each Permitted Free Writing Prospectus as an issuer free writing prospectus and
has complied and will comply with the requirements of Rule 164 and Rule 433 applicable to any Permitted Free Writing Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)
<I><U>Covenants of the Selling Stockholders</U></I>.&nbsp;The Selling Stockholders covenant and agree with the several Underwriters as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-27- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <I><U>Payment of Expenses</U></I>.&nbsp;Each Selling Stockholder will pay all
taxes, if any, on the transfer and sale, respectively, of the Securities being sold by such Selling Stockholder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)
<I><U>Reimbursement</U></I>.&nbsp;If this Agreement shall be terminated by the Underwriters because of any failure, refusal or inability on the part of any Selling Stockholder to perform any agreement on such Selling Stockholder&#146;s part to be
performed, or because any other condition of the Underwriters&#146; obligations hereunder required to be fulfilled by a Selling Stockholder is not fulfilled, such defaulting Selling Stockholders agree to reimburse the several Underwriters for all
out-of-pocket accountable disbursements (including fees and disbursements of counsel for the Underwriters) incurred by the Underwriters in connection with their investigation, preparing to market and marketing the Securities or in contemplation of
performing their obligations.&nbsp;Such reimbursement shall be paid by the defaulting Selling Stockholders in proportion to the number of Securities to be sold by each defaulting Selling Stockholder (including any Option Shares) bears to the total
number of Securities sold by all such defaulting parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) <I><U>No Market Stabilization or
Manipulation</U></I>.&nbsp;No Selling Stockholder has taken and will not take, directly or indirectly, any action designed to or which might reasonably be expected to cause or result in stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) <I><U>Continued Compliance with Securities
Laws</U></I>.&nbsp;Each Selling Stockholder shall immediately notify you if any event occurs, or of any change in the Selling Stockholder Information relating to such Selling Stockholder which results in the Time of Sale Disclosure Package or in the
Prospectuses (as amended or supplemented) or any Permitted Free Writing Prospectus including an untrue statement of a material fact or omitting to state any material fact necessary to make the statements therein, in light of the circumstances under
which they were made, not misleading.</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) <I><U>Form W-9</U></I>.&nbsp;Each Selling Stockholder shall deliver to the
Custodian or the Representative, as appropriate, prior to the First Closing Date, a properly completed and executed United States Treasury Department Form W-9 (or other applicable form or statement specified by Treasury Department regulations in
lieu thereof). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B><I>Conditions of Underwriters&#146; Obligations</I></B>.&nbsp;The obligations of the several Underwriters hereunder
are subject to the accuracy, as of the date hereof and at each of the First Closing Date and the Second Closing Date (as if made at such Closing Date), of and compliance with all representations, warranties and agreements of the Company and the
Selling Stockholder contained herein, to the performance by the Company and each Selling Stockholder of their respective obligations hereunder and to the following additional conditions: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-28- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <I><U>Required Filings; Absence of Certain Commission Actions</U></I>.&nbsp;If filing of the
Prospectuses, or any amendment or supplement thereto, or any issuer free writing prospectus, is required under the Securities Act or the Rules and Regulations, the Company shall have filed the Prospectuses (or such amendment or supplement) or such
issuer free writing prospectus with the Commission in the manner and within the time period so required (without reliance on Rule 424(b)(8) or Rule 164(b)); the Registration Statements shall remain effective; no stop order suspending the
effectiveness of the Registration Statements or any part thereof, any Rule 462(b) Registration Statement, or any amendment thereof, nor suspending or preventing the use of the Time of Sale Disclosure Package, the Prospectuses or any issuer free
writing prospectus shall have been issued; no proceedings for the issuance of such an order shall have been initiated or threatened; any request of the Commission for additional information (to be included in the Registration Statements, the Time of
Sale Disclosure Package, the Prospectuses, any issuer free writing prospectus or otherwise) shall have been complied with to your satisfaction.</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <I><U>Continued Compliance with Securities Laws</U></I>.&nbsp;No Underwriter shall have advised the Company that (i) the Registration
Statements or any amendment thereof or supplement thereto contains an untrue statement of a material fact which, in your opinion, is material or omits to state a material fact which, in your opinion, is required to be stated therein or necessary to
make the statements therein not misleading, or (ii) the Time of Sale Disclosure Package or the Prospectuses, or any amendment thereof or supplement thereto, or any issuer free writing prospectus contains an untrue statement of fact which, in your
opinion, is material, or omits to state a fact which, in your opinion, is material and is required to be stated therein, or necessary to make the statements therein, in light of the circumstances under which they are made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <I><U>Absence of Certain Events</U></I>.&nbsp;Except as contemplated in the Time of Sale Disclosure Package and in the Prospectuses,
subsequent to the respective dates as of which information is given in the Time of Sale Disclosure Package, neither the Company nor any subsidiary shall have incurred any material liabilities or obligations, direct or contingent, or entered into any
material transactions, or declared or paid any dividends or made any distribution of any kind with respect to its capital stock; and there shall not have been any change in the capital stock (other than a change in the number of outstanding shares
of Common Stock due to the issuance of shares upon the exercise of outstanding options or warrants or conversion of convertible securities), or any material change in the short-term or long-term debt of the Company (other than as a result of the
conversion of convertible securities), or any issuance of options, warrants, convertible securities or other rights to purchase the capital stock of the Company or any of its subsidiaries, or any Material Adverse Change or any development involving
a prospective Material Adverse Change (whether or not arising in the ordinary course of business), or any loss by strike, fire, flood, earthquake, accident or other calamity, whether or not covered by insurance, incurred by the Company or any
subsidiary, the effect of which, in any such case described above, in your judgment, makes it impractical or inadvisable to offer or deliver the Securities on the terms and in the manner contemplated in the Time of Sale Disclosure Package and in the
Prospectuses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d)<I><U> Opinion of Company Counsel</U></I>.&nbsp;On each Closing Date, there shall have been furnished to you, as
Representative of the several Underwriters, the opinion of Ruskin Moscou Faltischek, P.C., counsel for the Company, dated such Closing Date and addressed to you in form and substance satisfactory to you.</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <I>Opinion of Intellectual Property Company Counsel</I>.&nbsp;On each Closing Date, there shall have been furnished to you, as
Representative of the several Underwriters, the opinion of Hespos &amp; Porco, LLP, intellectual property counsel for the Company, dated such Closing Date and addressed to you in form and substance satisfactory to you.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-29- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;<I><U>Opinion of Selling Stockholders Counsel</U></I>.&nbsp;On each Closing Date, there
shall have been furnished to you, as Representative of the several Underwriters, the opinion of Morrison Cohen LLP, counsel for each Selling Stockholder, dated such Closing Date and addressed to you in form and substance satisfactory to the
Representative. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <I><U>Opinion of Underwriters&#146; Counsel</U></I>.&nbsp;On each Closing Date, there shall have been furnished to
you, as Representative of the several Underwriters, such opinion or opinions from Goodwin Procter LLP, counsel for the several Underwriters, dated such Closing Date and addressed to you, with respect to the formation of the Company, the validity of
the Securities, the Registration Statement, the Time of Sale Disclosure Package, the Prospectus and other related matters as you reasonably may request, and such counsel shall have received such papers and information as they request to enable them
to pass upon such matters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <I><U>Comfort Letter</U></I>.&nbsp;On the date hereof, on the effective date of any post-effective
amendment to the Registration Statement filed after the date hereof and on each Closing Date you, as Representative of the several Underwriters, shall have received an accountant&#146;s &#147;comfort&#148; letter of each of Frazier &amp; Deeter, LLC
and Kingery and Crouse, P.A., dated such date and addressed to you, in form and substance satisfactory to you. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <I><U>Officers&#146;
Certificate</U></I>.&nbsp;On each Closing Date, there shall have been furnished to you, as Representative of the Underwriters, a certificate, dated such Closing Date and addressed to you, signed by the chief executive officer and by the chief
financial officer of the Company, to the effect that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) The representations and warranties of the Company in this
Agreement are true and correct as if made at and as of such Closing Date, and the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to such Closing Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) No stop order or other order suspending the effectiveness of the Registration Statements or any part thereof or any
amendment thereof or the qualification of the Securities for offering or sale nor suspending or preventing the use of the Time of Sale Disclosure Package, the Prospectuses or any issuer free writing prospectus, has been issued, and no proceeding for
that purpose has been instituted or, to the best of their knowledge, is contemplated by the Commission or any state or regulatory body; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) Affirms the accuracy of the matters set forth in subsection (C) of this Section 5. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j) <I><U>Selling Stockholders Certificate</U></I>.&nbsp;On each Closing Date, there shall have been furnished to you, as Representative of the
several Underwriters, a certificate or certificates, dated such Closing Date and addressed to you, signed by each Selling Stockholder or such Selling Stockholder&#146;s Attorneys-in-Fact to the effect that the representations and warranties of such
Selling </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-30- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stockholder contained in this Agreement are true and correct as if made at and as of such Closing Date, and that such Selling Stockholder has complied with all the agreements and satisfied all
the conditions on the Selling Stockholder&#146;s part to be performed or satisfied at or prior to such Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(k) <I><U>Lock-Up
Agreement</U></I>.&nbsp;The Underwriters shall have received all of the Lock-Up Agreements referenced in Section 4 and the Lock-Up Agreements shall remain in full force and effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(l) <I><U>FINRA No Objections</U></I>.&nbsp;FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms
and arrangements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(m) <I><U>Other Documents</U></I>.&nbsp;The Company shall have furnished to you and counsel for the Underwriters such
additional documents, certificates and evidence as you or they may have reasonably requested. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(n) <I><U>Exchange Listing</U></I>.&nbsp;The
Securities to be delivered on such Closing Date have been approved for listing on the New York Stock Exchange, subject to official notice of issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All such opinions, certificates, letters and other documents will be in compliance with the provisions hereof only if they are satisfactory in
form and substance to you and counsel for the Underwriters.&nbsp;The Company will furnish you with such conformed copies of such opinions, certificates, letters and other documents as you shall reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B><I>Indemnification and Contribution</I></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <I><U>Indemnification by the Company</U></I>. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors
and officers and each person, if any, who controls such Underwriter within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, from and against any losses, claims, damages or liabilities, joint or several, to which such
Underwriter may become subject, under the Act or otherwise (including in settlement of any litigation if such settlement is effected with the written consent of the Company), insofar as such losses, claims, damages or liabilities (or actions in
respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in any Registration Statement, including the 430A Information and any other information deemed to be a part of the
Registration Statement at the time of effectiveness and at any subsequent time pursuant to the Rules and Regulations, if applicable, any Preliminary Prospectuses, the Time of Sale Disclosure Package, the Prospectuses, or any amendment or supplement
thereto, any issuer free writing prospectus, or any issuer information that the Company has filed or is required to file pursuant to Rule 433(d) of the Rules and Regulations, or arise out of or are based upon the omission or alleged omission to
state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse each Underwriter for any legal or other expenses reasonably incurred by it in connection with investigating or
defending against such loss, claim, damage, liability or action as such expenses are incurred; <I>provided, however,</I> that the Company will not be liable in any such case to the extent that any such loss, claim, damage, liability or action arises
out </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-31- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in
reliance upon and in conformity with written information furnished to the Company by you, or by any Underwriter through you, specifically for use in the preparation thereof; it being understood and agreed that the only information furnished by an
Underwriter consists of the information described as such in Section 6(f). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <I><U>Indemnification by the Selling
Stockholders</U></I>.&nbsp;The Selling Stockholders, severally and not jointly, agree to indemnify and hold harmless each Underwriter, its affiliates, directors and officers and each person, if any, who controls such Underwriter within the meaning
of Section 15 of the Act or Section 20 of the Exchange Act, from and against any losses, claims, damages or liabilities, joint or several, to which such Underwriter may become subject, under the Act or otherwise (including in settlement of any
litigation if such settlement is effected with the written consent of such Selling Stockholder), insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged
untrue statement of a material fact contained in the Registration Statement, including the 430B Information and any other information deemed to be a part of the Registration Statement at the time of effectiveness and at any subsequent time pursuant
to the Rules and Regulations, if applicable, any Preliminary Prospectus, the Time of Sale disclosure Package, the Prospectus, or any amendment or supplement thereto, any issuer free writing prospectus, or any issuer information that the Company has
filed or is required to file pursuant to Rule 433(d) of the Rules and Regulations, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements
therein not misleading, and will reimburse each Underwriter for any legal or other expenses reasonably incurred by it in connection with investigating or defending against such loss, claim, damage, liability or action as such expenses are incurred;
<I>provided, however,</I> that (x) each Selling Stockholder shall be liable in any such case only to the extent that any such loss, claim, damage, liability or action arises out of or is based upon an untrue statement or alleged untrue statement or
omission or alleged omission made in reliance upon and in conformity such Selling Stockholder Information relating to each Selling Stockholder, and (y) in no event shall a Selling Stockholder&#146;s liability hereunder exceed the aggregate amount of
net proceeds (after deducting Underwriters&#148; discounts and commissions) received by such Selling Stockholder from the sale of the Securities pursuant to this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <I><U>Indemnification by the Underwriters</U></I>.&nbsp;Each Underwriter will, severally and not jointly, indemnify and hold harmless the
Company and each Selling Stockholder, its affiliates, directors and officers and each person, if any, who controls the Company and any Selling Stockholder within the meaning of Section 15 of the Act and Section 20 of the Exchange Act, from and
against any losses, claims, damages or liabilities to which the Company and the Selling Stockholders may become subject, under the Act or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent
of such Underwriter), insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in the Registration Statements,
any Preliminary Prospectuses, the Time of Sale Disclosure Package, the Prospectuses, or any amendment or supplement thereto, or any issuer free writing prospectus, or any issuer information that the Company has filed or is required to file pursuant
to Rule 433(d) of the Rules and Regulations, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-32- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue
statement or omission or alleged omission was made in reliance upon and in conformity with written information furnished to the Company by you, or by such Underwriter through you, specifically for use in the preparation thereof (it being understood
and agreed that the only information furnished by an Underwriter consists of the information described as such in Section 6(f)), and will reimburse the Company and each Selling Stockholder for any legal or other expenses reasonably incurred by the
Company or any such Selling Stockholder in connection with investigating or defending against any such loss, claim, damage, liability or action as such expenses are incurred. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <I><U>Notice and Procedures</U></I>.&nbsp;Promptly after receipt by an indemnified party under subsection (a), (b) or (c) above of notice
of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of the commencement thereof; but the omission
so to notify the indemnifying party shall not relieve the indemnifying party from any liability that it may have to any indemnified party except to the extent such indemnifying party has been materially prejudiced by such failure (through the
forfeiture of substantive rights or defenses). In case any such action shall be brought against any indemnified party, and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate
in, and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel satisfactory to such indemnified party, and after notice from the indemnifying party to such
indemnified party of the indemnifying party&#146;s election so to assume the defense thereof, the indemnifying party shall not be liable to such indemnified party under such subsection for any legal or other expenses subsequently incurred by such
indemnified party in connection with the defense thereof other than reasonable costs of investigation; <I>provided</I>, <I>however</I>, that if, in the sole judgment of the Representative, it is advisable for the Underwriters to be represented as a
group by separate counsel, the Representative shall have the right to employ a single counsel (in addition to local counsel) to represent the Representative and all Underwriters who may be subject to liability arising from any claim in respect of
which indemnity may be sought by the Underwriters under subsection (a) or (b) of this Section 6, in which event the reasonable fees and expenses of such separate counsel shall be borne by the indemnifying party or parties and reimbursed to the
Underwriters as incurred.&nbsp;An indemnifying party shall not be obligated under any settlement agreement relating to any action under this Section 6 to which it has not agreed in writing.&nbsp;In addition, no indemnifying party shall, without the
prior written consent of the indemnified party (which consent shall not be unreasonably withheld or delayed, effect any settlement of any pending or threatened proceeding unless such settlement includes an unconditional release of such indemnified
party for all liability on claims that are the subject matter of such proceeding and does not include a statement as to, or an admission of, fault, culpability or a failure to act by or on behalf of an indemnified party.&nbsp;Notwithstanding the
foregoing, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel pursuant to this Section 6(d), such indemnifying party agrees that it shall be liable for
any settlement effected without its written consent if (i) such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request and (ii) such indemnifying party shall not have reimbursed such
indemnified party in accordance with such request prior to the date of such settlement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-33- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <I><U>Contribution; Limitations on Liability; Non-Exclusive Remedy</U></I>.&nbsp;If the
indemnification provided for in this Section 6 is unavailable or insufficient to hold harmless an indemnified party under subsection (a), (b) or (c) above, then each indemnifying party shall contribute to the amount paid or payable by such
indemnified party as a result of the losses, claims, damages or liabilities referred to in subsection (a), (b) or (c) above, (i) in such proportion as is appropriate to reflect the relative benefits received by the Company and each Selling
Stockholder on the one hand and the Underwriters on the other from the offering of the Securities or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only the
relative benefits referred to in clause (i) above but also the relative fault of the Company and the Selling Stockholders on the one hand and the Underwriters on the other in connection with the statements or omissions that resulted in such losses,
claims, damages or liabilities, as well as any other relevant equitable considerations.&nbsp;The relative benefits received by the Company and each Selling Stockholder shall be deemed in proportion to the total net proceeds from the offering (before
deducting expenses) received by the Company and each Selling Stockholder and the benefits received by the&nbsp;Underwriters shall be deemed to be in the same proportion as they bear to the total underwriting discounts and commissions received by the
Underwriters, in each case as set forth in the table on the cover page of the Prospectuses.&nbsp;The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the
omission or alleged omission to state a material fact relates to information supplied by the Company, each Selling Stockholder or the Underwriters and the parties&#146; relevant intent, knowledge, access to information and opportunity to correct or
prevent such untrue statement or omission.&nbsp;The Company, each Selling Stockholder and the Underwriters agree that it would not be just and equitable if contributions pursuant to this subsection (e) were to be determined by pro rata allocation
(even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in the first sentence of this subsection (e).&nbsp;The amount paid by
an indemnified party as a result of the losses, claims, damages or liabilities referred to in the first sentence of this subsection (e) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in
connection with investigating or defending against any action or claim which is the subject of this subsection (e).&nbsp;Notwithstanding the provisions of this subsection (e),&nbsp;(i) no Underwriter shall be required to contribute any amount in
excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the Securities purchased by it hereunder exceeds the amount of any damages that such Underwriter has otherwise been required
to pay by reason of such untrue or alleged untrue statement or omission or alleged omission&nbsp;and (ii) the liability under this subsection of each Selling Stockholder shall be limited to an amount equal to the aggregate gross proceeds after
underwriting discounts and commissions, but before expenses, to such Selling Stockholder from the sale of Securities sold by such Selling Stockholder hereunder.&nbsp;No person guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.&nbsp;The Underwriters&#146; obligations in this subsection (e) to contribute are several in proportion to their respective
underwriting obligations and not joint.&nbsp;The remedies provided for in this Section 6 are not exclusive and shall not limit any rights or remedies that might otherwise be available to any indemnified party at law or in equity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-34- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <I><U>Information Provided by the Underwriters</U></I>.&nbsp;The Underwriters severally
confirm and the Company and each Selling Stockholder acknowledges that the statements with respect to the public offering of the Securities by the Underwriters set forth second, eighth and ninth paragraphs under the caption &#147;Underwriting&#148;
in the Time of Sale Disclosure Package and in the Prospectuses constitute the only information concerning such Underwriters furnished in writing to the Company by or on behalf of the Underwriters specifically for inclusion in the Preliminary
Prospectuses, the Time of Sale Disclosure Package, the Prospectuses or any issuer free writing prospectus.</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <B><I>Representations and
Agreements to Survive Delivery</I></B>.&nbsp;All representations, warranties, and agreements of the Company and the Selling Stockholder herein or in certificates delivered pursuant hereto, including but not limited to the agreements of the several
Underwriters, the Company and each Selling Stockholder contained in Section 6 hereof, shall remain operative and in full force and effect regardless of any investigation made by or on behalf of any Underwriter or any controlling person thereof, or
the Company or any of its officers, directors, or controlling persons, or each Selling Stockholder or any controlling person thereof, and shall survive delivery of, and payment for, the Securities to and by the Underwriters hereunder and any
termination of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <B><I>Substitution of Underwriters</I></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <I><U>Obligation to Purchase Under Certain Circumstances</U></I>. If any Underwriter or Underwriters shall fail to take up and pay for the
amount of Firm Shares agreed by such Underwriter or Underwriters to be purchased hereunder, upon tender of such Firm Shares in accordance with the terms hereof, and the amount of Firm Shares not purchased does not aggregate more than 10% of the
total amount of Firm Shares set forth in <U>Schedule II</U> hereto, the remaining Underwriters shall be obligated to take up and pay for (in proportion to their respective underwriting obligations hereunder as set forth in Schedule II hereto except
as may otherwise be determined by you) the Firm Shares that the withdrawing or defaulting Underwriters agreed but failed to purchase. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b)
<I><U>Termination Under Certain Circumstances</U></I>.&nbsp;If any Underwriter or Underwriters shall fail to take up and pay for the amount of Firm Shares agreed by such Underwriter or Underwriters to be purchased hereunder, upon tender of such Firm
Shares in accordance with the terms hereof, and the amount of Firm Shares not purchased aggregates more than 10% of the total amount of Firm Shares set forth in Schedule II hereto, and arrangements satisfactory to you for the purchase of such Firm
Shares by other persons are not made within 36 hours thereafter, this Agreement shall terminate.&nbsp;In the event of any such termination neither the Company nor any Selling Stockholder shall be under any liability to any Underwriter (except to the
extent provided in Section 4(a)(vii), Section 4(b)(i), Section 4(b)(ii) and Section 6 hereof) nor shall any Underwriter (other than an Underwriter who shall have failed, otherwise than for some reason permitted under this Agreement, to purchase the
amount of Firm Shares agreed by such Underwriter to be purchased hereunder) be under any liability to the Company or any Selling Stockholder (except to the extent provided in Section 6 hereof). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-35- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <I><U>Postponement of Closing</U></I>.&nbsp;If Firm Shares to which a default relates are to
be purchased by the non-defaulting Underwriters or by any other party or parties, the Representative or the Company shall have the right to postpone the First Closing Date for not more than seven business days in order that the necessary changes in
the Registration Statement, in the Time of Sale Disclosure Package, in the Prospectus or in any other documents, as well as any other arrangements, may be effected.&nbsp;As used herein, the term &#147;Underwriter&#148; includes any person
substituted for an Underwriter under this Section 8. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <I><U>No Relief from Liability</U></I>.&nbsp;No action taken pursuant to this
Section shall relieve any defaulting Underwriter from liability, if any, in respect of such default. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <B><I>Termination of this
Agreement.</I></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <I><U>Right to Terminate</U></I>. You, as Representative of the several Underwriters, shall have the right to
terminate this Agreement by giving notice to the Company and each Selling Stockholder as hereinafter specified at any time at or prior to the First Closing Date, and the option referred to in Section 3(b), if exercised, may be cancelled at any time
prior to the Second Closing Date, if (i) the Company or any Selling Stockholder shall have failed, refused or been unable, at or prior to such Closing Date, to perform any agreement on its or their part to be performed hereunder, (ii) any condition
of the Underwriters&#146; obligations hereunder is not fulfilled, (iii) trading in the Company&#146;s Common Stock shall have been suspended by the Commission or New York Stock Exchange&nbsp;or trading in securities generally on the NASDAQ Stock
Market or New York Stock Exchange shall have been suspended, (iv) minimum or maximum prices for trading shall have been fixed, or maximum ranges for prices for securities shall have been required, on the NASDAQ Stock Market or New York Stock
Exchange, by such Exchange or by order of the Commission or any other Governmental Authority having jurisdiction, (v) a banking moratorium shall have been declared by federal or New York state authorities or a material disruption in commercial
banking or securities settlement or clearance services in the United States, or (vi) there shall have occurred any attack on, outbreak or escalation of hostilities or act of terrorism involving the United States, any declaration by the United States
of a national emergency or war, any change in financial markets, any substantial change or development involving a prospective substantial change in United States or international political, financial or economic conditions, or any other calamity or
crisis that, in your judgment, is material and adverse and makes it impractical or inadvisable to proceed with the completion of the sale of and payment for the Securities.&nbsp;Any such termination shall be without liability of any party to any
other party except that the provisions of Section 4(a)(vii), Section 4(b)(i), Section 4(b)(ii) and Section 6 hereof shall at all times be effective and shall survive such termination. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <I><U>Notice of Termination</U></I>.&nbsp;If you elect to terminate this Agreement as provided in this Section, the Company and an
Attorney-in-Fact, on behalf of the Selling Stockholder, shall be notified promptly by you by telephone, confirmed by letter.</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.
<B><I>Default by any Selling Stockholder or the Company</I></B>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <I><U>Default by the Selling Stockholder</U></I>. If any Selling
Stockholder shall fail at the First Closing Date to sell and deliver the number of Securities which such Selling Stockholder is obligated to sell hereunder, then the Underwriters may at your option, by notice from you to the Company, either (i)
terminate this Agreement without any liability on the part of any Underwriter or, except as provided in Section 4(a)(vii), Section 4(b)(i), Section 4(b)(ii) and Section 6 hereof, any non-defaulting party or (ii) elect to purchase the Securities
which the Company has agreed to sell hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-36- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <I><U>Default by the Company</U></I>.&nbsp;If the Company shall fail at the First Closing
Date to sell and deliver the number of Securities which it is obligated to sell hereunder, then this Agreement shall terminate without any liability on the part of any Underwriter or, except as provided in Section 4(a)(vii), Section 4(b)(i), Section
4(b)(ii) and Section 6 hereof, any non-defaulting party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <I><U>No Relief from Liability</U></I>.&nbsp;No action taken pursuant to this
Section shall relieve the Company or the Selling Stockholder so defaulting from liability, if any, in respect of such default. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.
<B><I>Notices</I></B>.&nbsp;Except as otherwise provided herein, all communications hereunder shall be in writing and, if to the Underwriters, shall be mailed via overnight delivery service or hand delivered via courier to the Representative c/o
Piper Jaffray &amp; Co., U.S. Bancorp Center, 800 Nicollet Mall, Minneapolis, Minnesota 55402, Attention: Equity Capital Markets, with a copy to General Counsel; if to the Company, shall be mailed or delivered to it at 4 Manhattanville Road, Suite
106, Purchase, New York 10577, Attention: Chief Executive Officer); if to any of the Selling Stockholders, shall be mailed or delivered to them at the 165 Mason Street, 3rd Floor, Greenwich, CT 06830, Attention: Chief financial Officer, or in each
case to such other address as the person to be notified may have requested in writing.&nbsp;Any party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <B><I>Persons Entitled to Benefit of Agreement</I></B>.&nbsp;This Agreement shall inure to the benefit of and be binding upon the
parties hereto and their respective successors and assigns and the controlling persons, officers and directors referred to in Section 6.&nbsp;Nothing in this Agreement is intended or shall be construed to give to any other person, firm or
corporation any legal or equitable remedy or claim under or in respect of this Agreement or any provision herein contained.&nbsp;The term &#147;successors and assigns&#148; as herein used shall not include any purchaser, as such purchaser, of any of
the Securities from any of the several Underwriters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <B><I>Absence of Fiduciary Relationship</I></B>.&nbsp;The Company and each
Selling Stockholder acknowledges and agrees that: (a) the Representative has been retained solely to act as an underwriter in connection with the sale of the Securities and that no fiduciary, advisory or agency relationship between the Company or
any Selling Stockholder and the Representative has been created in respect of any of the transactions contemplated by this Agreement, irrespective of whether the Representative has advised or is advising the Company or the Selling Stockholder on
other matters; (b) the price and other terms of the Securities set forth in this Agreement were established by the Company and each Selling Stockholder following discussions and arms-length negotiations with the Representative and the Company and
each Selling Stockholder is capable of evaluating and understanding and understands and accepts the terms, risks and conditions of the transactions contemplated by this Agreement; (c) it has been advised that the Representative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-37- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and its affiliates are engaged in a broad range of transactions which may involve interests that differ from
those of the Company and each Selling Stockholder and that the Representative has no obligation to disclose such interest and transactions to the Company or the Selling Stockholders by virtue of any fiduciary, advisory or agency relationship; (d) it
has been advised that the Representative is acting, in respect of the transactions contemplated by this Agreement, solely for the benefit of the Representative and the other Underwriters, and not on behalf of the Company or any Selling Stockholder;
(e) it, he or she waives to the fullest extent permitted by law, any claims it may have against the Representative for breach of fiduciary duty or alleged breach of fiduciary duty in respect of any of the transactions contemplated by this Agreement
and agrees that the Representative shall have no liability (whether direct or indirect) to the Company or any Selling Stockholder in respect of such a fiduciary duty claim on behalf of or in right of the Selling Stockholders or the Company,
including stockholders, employees or creditors of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <B><I>Governing Law; Waiver of Jury Trial</I></B>.&nbsp;This Agreement
shall be governed by and construed in accordance with the laws of the State of New York.&nbsp;The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates), each of the Selling Stockholder
and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated
hereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <B><I>Counterparts</I></B>.&nbsp;This Agreement may be executed in one or more counterparts and, if executed in more than one
counterpart, the executed counterparts shall each be deemed to be an original and all such counterparts shall together constitute one and the same instrument. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.<B><I> General Provisions.</I></B>&nbsp;This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all
prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof.&nbsp;This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no
condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit.&nbsp;The Section headings herein are for the convenience of the parties only and shall not affect the construction or
interpretation of this Agreement.&nbsp;The invalidity or unenforceability of any Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other Section, paragraph or provision hereof.&nbsp;If any
Section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-38- </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please sign and return to the Company the enclosed duplicates of this letter whereupon this letter will become a
binding agreement between the Company, the Selling Stockholders and the several Underwriters in accordance with its terms. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>BOVIE MEDICAL CORPORATION</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Robert Gershon</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Robert Gershon</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>B<SMALL>IOMEDICAL</SMALL> V<SMALL>ALUE</SMALL> F<SMALL>UND</SMALL>, L.P.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>B<SMALL>IOMEDICAL</SMALL> I<SMALL>NSTITUTIONAL</SMALL> V<SMALL>ALUE</SMALL> F<SMALL>UND</SMALL>, L.P.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>B<SMALL>IOMEDICAL</SMALL> O<SMALL>FFSHORE</SMALL> V<SMALL>ALUE</SMALL> F<SMALL>UND</SMALL>, L<SMALL>TD</SMALL>.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WS I<SMALL>NVESTMENTS</SMALL> II, LLC</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>C<SMALL>LASS</SMALL> D S<SMALL>ERIES</SMALL> <SMALL>OF</SMALL> GEP-PS, L.P.</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>By: Great Point Partners, LLC</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Its: Investment
Manager</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ David Kroin</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">David Kroin</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Confirmed as of the date first above mentioned, on behalf of themselves and the other several Underwriters named in Schedule II
hereto.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>IPER</SMALL> J<SMALL>AFFRAY</SMALL> &amp;
C<SMALL>O</SMALL>.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">


<IMG SRC="g287359dsp046.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Managing Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page for Underwriting Agreement] </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE I </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Selling Stockholders </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Number of</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Maximum&nbsp;Number&nbsp;of</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Firm&nbsp;Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Option&nbsp;Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:19.10pt; font-size:8pt; font-family:Times New Roman">Name</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">to be Sold</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Subject to Option</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biomedical Value Fund, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biomedical Institutional Value Fund, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biomedical Offshore Value Fund, Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">397,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">WS Investments II, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class D Series of GEF-PS, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE II </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.05pt; font-size:8pt; font-family:Times New Roman">Underwriter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of&nbsp;Firm&nbsp;Shares&nbsp;(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Piper Jaffray &amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The Underwriters may purchase up to an additional 450,000 Option Shares, to the extent the option described in Section 3(b) of the Agreement is exercised, in the proportions and in the manner described in the Agreement.
</TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE III </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain Permitted Free Writing Prospectuses </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE IV </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Subsidiaries </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aaron Medical Industries,
Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bovie Bulgaria </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EOOD </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BVX Holdings LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bovie Holdings, Inc. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE V </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pricing Information </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Firm Shares:
3,000,000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Option Shares: 450,000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Public Offering Price:
$4.00 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriting Discount Per Share: $0.24 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE VI </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>List of Individuals and Entities Executing Lock-Up Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Andrew Makrides </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Robert L. Gershon </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J. Robert Saron </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moshe Citronowicz </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Andres </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles Orsatti </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay D. Ewers </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John J. McCarthy </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael E. Geraghty </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lawrence Waldman </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BioMedical Value Fund, L.P. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BioMedical Institutional Value Fund,
L.P. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BioMedical Offshore Value Fund, Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WS Investments
II, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class D Series of GEF-PS, L.P. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of Lock-Up Agreement </B></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d287359dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Bovie Medical Prices Public Offerings of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CLEARWATER, FL &#150;&nbsp;November 10, 2016 &#150; Bovie Medical Corporation (NYSEMKT:BVX)</B> (the &#147;Company&#148;), a maker of medical devices and
supplies and the developer of J-Plasma<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, a patented new surgical product, announced today the pricing of its previously announced underwritten public offerings of 3,000,000 shares of its
common stock at a public offering price of $4.00 per share. Bovie Medical is offering 1,500,000 shares and certain selling stockholders are offering 1,500,000 shares of common stock. In connection with the offerings, Bovie Medical&nbsp;and the
selling stockholders have granted the underwriter a 30-day option to purchase up to an additional 450,000 shares of common stock to cover over-allotments, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cumulative gross proceeds of the offerings, excluding the proceeds from any over-allotments, are expected to be $12.0 million, of which the gross proceeds to
Bovie Medical are expected to be $6.0 million. Bovie Medical will use its proceeds from the offering to expand its sales and marketing activities, to expand its research and development efforts, to conduct clinical trials, and for general corporate
purposes and working capital.&nbsp;The offering is subject to customary closing conditions and is expected to close on November&nbsp;15, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piper
Jaffray is acting as sole manager of the offerings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The offerings were made pursuant to shelf registration statements previously filed with the
Securities and Exchange Commission (the &#147;SEC&#148;), which the SEC declared effective. A preliminary prospectus supplement has been filed with the SEC for each of the offerings and a final prospectus supplement relating to each offering will be
filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus relating to these securities may be obtained, when available, by contacting Piper Jaffray&nbsp;&amp; Co., Attention: Prospectus Department, 800 Nicollet Mall,
J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at prospectus@pjc.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release is for informational purposes only
and shall not constitute an offer to sell or a solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state or jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Bovie Medical Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of
J-Plasma<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> utilizes a helium ionization process to
produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture
of a range of electrosurgical products and technologies, marketed through both private labels and the Company&#146;s own well-respected brands (Bovie<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Aaron<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, IDS&#153; and ICON&#153;) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers.
For further information about the Company&#146;s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation&#146;s website&nbsp;www.boviemed.com. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Statement on Forward-Looking Statements </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable
assumptions, it can give no assurance that its expectations will be achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking information is subject to certain risks, trends and
uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company&#146;s ability to control or predict. Important factors that may cause actual results to differ materially and that
could impact the Company and the statements contained in this release can be found in the Company&#146;s filing with the Securities and Exchange Commission including the Company&#146;s Report on Form 10-K for the year ended December&nbsp;31, 2015
and subsequent 10-Q filings. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes
no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor
Relations: </B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MBS Value Partners </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lynn Morgen/ Jane Searle
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">212 750&nbsp;5800 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">investor.relations@boviemed.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g287359dsp046.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g287359dsp046.jpg
M_]C_X0O:17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-CHQ,3HQ,2 P-3HP.#HQ,P   Z !
M  ,    !__\  * "  0    !    E: #  0    !    +P         & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M=1C?\<DIW<O-P\&AV1FWUXU#?I6VN#&B?Y;RUJCT_J&'U+#KS<&P78UP)KL
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MW85^%XD%-CA"24T$.@      ]P   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M"@!( %  +0!& %  1P M #4 -       #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 2P    !
M  (!+     $  CA"24T$)@      #@             _@   .$))300-
M   $    >#A"24T$&0      !    !XX0DE- _,       D           $
M.$))32<0       *  $          CA"24T#]0      2  O9F8  0!L9F8
M!@       0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M     0 M    !@       3A"24T#^       <   ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@     ____________________________
M_P/H   X0DE-! @      !     !   "0    D      .$))300>       $
M     #A"24T$&@     #4P    8              "\   "5    #P R #@
M-P S #4 .0 @ $4 6  Q %\ ,0 M #0 ,0    $
M     0              E0   "\                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<    O     %)G:'1L;VYG    E0    -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $     CA"24T$#      *P     $   "5
M+P   <   %)    *I  8  '_V/_M  Q!9&]B95]#30 !_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ +P"5 P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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M '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8
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MOZ[VI2Q5VZ=_=B;IP>R=E[:HIJNGH(:S/[IW+78S!X>EEKJN*%9*B>-&EE1
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MSY!?*"LQ61R.'Q^=A^/'5Z2Y/'XQZD/E=S5>(HA#4I421-[KW1FOBITAT?\
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BK'+)%6STS>Z]U=I[]U[KWOW7NO>_=>Z][]U[KWOW7NO_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
